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Abstract 
 
Effect of Anions on the Iron Release Pathways of Human Serum Transferrin  
(May 2010) 
 
Rashmi S. Sharma 
 
Chair of committee: Dr. Wesley R. Harris 
 
Transferrin, the serum iron transport protein in humans, is used to transport 30-40 
mg of iron per day through blood.  The accessibility of transferrin makes it an attractive 
target for iron chelating therapeutic agents used in the treatment of iron overload.  There 
is an ongoing search for ligands which can accelerate the rate of iron release, as the 
currently approved drug DFO has a very slow rate for iron removal.  Previous studies 
have shown that anions can accelerate the rate of iron release.  
 Studies on the effect of anions on the rates of iron release from C-terminal 
monoferric transferrin at pH 7.4 have been conducted using the ligands acetohydroxamic 
acid (AHA) and 1,2-dimethyl-3-hydroxy-pyridinone (L1), which follow saturation 
kinetics, and the ligands, nitrilotriacetic acid (NTA) and diethylenetriaminepentaacetic 
acid (DTPA), which follow first order kinetics with respect to the ligand concentration. 
The effects of sulfonates, phosphonates and phosphonocarboxylates have been studied.   
 The anions are divided into two types, simple (non-coordinating) and complex 
(capable of chelating iron).  The simple anions accelerate the rate of iron release, 
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presumably by binding to an allosteric anion binding site on the transferrin.  This binding 
increase the value of kmax for the saturation pathway for AHA and L1 and introduces a 
kmax for NTA, which otherwise does not have a saturation component. This changes the 
kinetic behavior of NTA from a strictly first-order dependence on the ligand 
concentration to complex kinetics, a combination of saturation and first-order kinetics.  
 The complex anions, which can also chelate iron, decrease the rate of iron release 
by the reference ligands.  These anions can also generate a small first order component 
for iron removal by ligands that normally follow saturation kinetics.  These studies 
emphasize that the appearance of the first order component is due to the replacement of 
synergistic anion by the incoming chelating ligand and is not an allosteric effect of the 
anionic ligand.  Distinct effects of anions on the saturation and first-order components for 
iron release are reported.  For NTA, the major impact of anions is a decrease in the value 
of k`.   
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Chapter 1 
Introduction 
 
This introductory chapter gives an overview of the progress of transferrin 
research.  It explains the requirement of iron transport proteins in humans, and describes 
the different analogs of transferrin that have been found in other species.  Research on the 
structure of the protein and how structure influences the function of protein is described.  
A detailed study of the binding of anions to transferrin and its impact on the binding and 
release of iron is included.  The main emphasis of this chapter is on the mechanism of 
iron release from transferrin by low-molecular-weight chelating agents. 
 
1.1 
Chemistry and Biochemistry of Iron 
 Iron is an element located at position 26 in the middle of the periodic table, in the 
first row of transition metals.  Iron exists in oxidation states ranging from (−II), as in the 
Fe(CO)42- anion, to (+VI), as in the ferrate ion FeO42- (1).  The two most relevant 
oxidation states in which iron exists biochemically are ferrous, Fe(II) and ferric, Fe(III), 
followed by Fe(IV) and Fe(V), which have been identified as reactive intermediates in 
the catalytic cycles of iron-containing enzymes such as monooxygenases (2;3). 
 Iron is an essential element for life, and it plays important roles in biology.  The 
total iron found in the body of an adult human is normally between 3-5 g, and on a daily 
basis about 0.5-2 mg of iron enters and leaves the body (3).  As there is no regulated 
pathway for iron excretion, iron balance in the body is maintained by regulation of iron 
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store most of the body’s excess iron, and small amounts of iron are used by other tissues 
(3).  The circulating iron is transported to red blood cell precursors and to other tissues of 
the body by the plasma protein transferrin (5).  During iron deficiency, the formation of 
red blood cells continues at the expense of other tissues.  In the case of iron overload, the 
production of red blood cells continues normally, and other tissues store the excess iron.  
The liver takes up most excess iron, followed by cardiac, pancreatic and other cells in the 
body (4). 
 Nature faces an interesting problem while dealing with iron.  Iron metabolism 
requires both the ferrous and ferric states of iron.  The presence of free ferrous ion is 
dangerous, as it can promote free radical formation via Fenton-type reactions as shown in 
Figure 1.2. 
 
 
 
Figure 1.2.  Formation of hydroxyl radical via Fenton-type reactions (6) 
 
 The free superoxide and hydroxyl radicals are highly toxic and can cause 
oxidative damage to the tissues.  To use the ferrous form of iron, nature has devised the 
oxygen transport protein haemoglobin (3), which can stabilize the ferrous oxidation state 
and prevent the damage.  On the other hand, free ferric form is highly insoluble due to its 
strong tendency to hydrolyze to ferric hydroxide (1).  For iron transport to occur the ferric 
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ion must be solubilized and stabilized as Fe(III) by a suitable complexing agent, and this 
need is fulfilled by the iron transport protein, transferrin (7). 
 
1.2 
Transferrins 
 Transferrins are metal binding proteins.  This family consists mainly of soluble 
glycoproteins, as well as the membrane bound protein melanotransferrin (8).  The soluble 
glycoproteins include serum transferrin, lactoferrin and ovotransferrin.  Serum transferrin 
is the iron binding protein found in the blood of most vertebrates (9).  Lactoferrin is 
found in secretory fluids like milk, tears, saliva etc., where it acts as a bacteriostatic agent 
by denying the essential nutrient iron to microorganisms (10;11).  Ovotransferrin, also 
referred to as conalbumin, is found in avian eggs and also serves a bacteriostatic function 
(3;10).  Melanotransferrin is present at very low levels on the surface of normal cells and 
at high levels in melanoma cells and is also known as melanoma antigen p97 (12;13).  A 
number of roles have been proposed for melanotransferrin in various physiological and 
pathological processes, including iron transport, chondrogenesis, angiogenesis, cell 
migration, invasion, metastasis, tumourigenesis and the regulation of plasminogen 
activation, though the precise role of melanotransferrin is unclear (14). 
Transferrins are considered to have evolved through a gene duplication event (10) 
from the gene of a 40 kDa, single binding site ancestral protein to a double binding site 
bilobal molecule, as shown in Figure 1.3.  Recently more work has focused on a class of 
single-site periplasmic iron binding proteins known as ferric binding protein (FBP) 
(15;16).  The ferric binding proteins are often referred to as bacterial transferrins and are 
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thought to be distantly related to the true mammalian transferrins, as they share several 
physical and functional properties with serum transferrin (17-19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Evolutionary development of the transferrin family (10) 
 
 Before any structural information was available, the transferrins were identified 
by the unique property that the binding of the iron required the concomitant binding of a 
bicarbonate anion from the buffer (20).  In the absence of bicarbonate, no metal binding 
was observed (21;22).  For this reason, bicarbonate is referred to as the “synergistic 
anion”. 
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 Crystal structures of various forms of transferrin, such as diferric rabbit serum 
transferrin (23), human diferric lactoferrin (11), human apolactoferrin (24), apo 
ovotransferrin (25), monoferric human serum transferrin (26), human serum 
apotransferrin (27), and the recombinant N-lobe of human serum transferrin (28) have 
been determined.  All the transferrins consist of a single polypeptide chain of 600-700 
amino acid residues with a molecular mass of around 80 kDa.  This polypeptide chain 
folds into two distinct lobes, designated as the N- and C- lobes.  Each lobe is subdivided 
into two domains (N-I, N-II and C-I, C-II).  A single iron binding site is located between 
the N-I and N-II and C-I and C-II domains, which form an iron binding cleft as shown in 
Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  The characteristic polypeptide folding pattern of the transferrin family 
(29) 
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 Crystal structures of apo- and holotransferrin have shown that at the base of the 
iron binding cleft, there is a hinge that contributes to a large scale conformational change 
in the protein when iron is removed (27;30).  Figure 1.5, depicts the conformation change 
in the N-lobe of human transferrin that occurs upon iron binding.  A 63˚ rigid rotation of 
the N-II domain occurs when iron is removed from the closed iron-bound form to the 
open apo form (30).  In the hinge region, the two helices in blue act as a fulcrum, where 
one supports the other to facilitate the movement. 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Two conformational states of the transferrin N-lobe showing the hinge 
region (31) 
 
1.3. 
Metal Binding site 
 The binding site ligands in most of the transferrins, including serum transferrin, 
lactoferrin and ovotransferrin, are the same for both the N- and C- lobe.  The metal ion is 
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bound to the phenolic groups of two tyrosines (Tyr 95 and 188 in the N lobe and Tyr 426 
and 517 in the C lobe), the imidazole group of one histidine (His 249 in the N lobe and 
His 585 in the C lobe) and the carboxylate side chain of an aspartic acid (Asp 63 in the N 
lobe and Asp 392 in the C lobe) (26;28).  The fifth and sixth coordination sites are filled 
by the synergistic carbonate anion, which acts as a bidentate ligand to the iron and also 
hydrogen bonds to residues at the terminus of a nearby α-helix (26;28).  Figure 1.6, 
shows the iron binding site in N-terminal monoferric transferrin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.  A representation of iron binding site in N-terminal human serum 
transferrin depicting the ligating residues and the synergistic carbonate anion 
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 Apart from binding Fe3+, a large number of di-, tri- and tetravalent metal ions 
have been reported to bind transferrins and are shown in Table 1.1.  Normally serum 
transferrin tends to be about 30 % saturated with iron, so the remaining 70% is free to 
bind other metals (32).  Even though these metals bind to transferrin, the affinity for Fe3+ 
remains the strongest. 
 
Table 1.1. 
 Metal ions reported to bind transferrins (33)  
 
Transition Metal Ions V3+, Cr3+, Mn2+/3+, Fe2+/3+, Co2+/3+, Ni2+, Cu2+, Zn2+, Cd2+, 
Hf4+, Sc3+ 
Lanthanides Ce3+/4+, Pr3+, Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Ho3+, Er3+, 
 Yb3+, Lu3+ 
Actinides Th4+, U4+, UO22+, Np4+, Pa4+, Pu4+, Am3+, Cm3+ 
P-Block Metal Ions Al3+, Ga3+, In3+, Tl3+, Bi3+ 
 
 The binding of transferrins to the various metal ions has given rise to multiple 
applications.  These metals can be categorized in groups depending on their importance:  
Tb3+, Eu3+, and Cu2+ are spectroscopically relevant, Mn2+ and Cr3+ are physiologically 
relevant, Al3+, Th4+, and Pu4+ are toxicologically relevant, and In3+ and Ga3+ are 
radiopharmaceutically important (34-37). 
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1.4 
Anions in transferrin research 
1.4.1. 
Synergistic and nonsynergistic anions 
 Anions studied in the field of transferrin research have been categorized into two 
classes.  The first class includes anions that participate in the binding of the iron to the 
protein and are described as “synergistic anions”.  The second class includes anions that 
are not involved in the binding of iron to the protein and are termed as “nonsynergistic 
anions”.  The requirement of a synergistic anion for metal binding is a unique feature of 
all transferrins.  In human serum transferrin carbonate is the synergistic anion required 
under physiological conditions.  The synergistic relationship between the carbonate and 
iron is due to the interdependence of both on each other for tight binding (22).  In the 
absence of the metal, the anion binds weakly to apotransferrin, and in the absence of a 
synergistic anion, ferric ion hydrolyses rather than bind to apotransferrin. 
 In the early days of transferrin research, there were attempts to form a binary Fe-
Tf complex in the absence of the carbonate synergistic anion.  These all failed, and it is 
now universally accepted that Fe3+, and most other metal ions, will not bind to apoTf in 
the absence of a synergistic anion (20-22).  However, carbonate is not the only possible 
synergistic anion.  A study of over 30 anion candidates was done by Schlabach and Bates 
(38).  If carbonate is carefully excluded from the solution, then several carboxylic acids, 
such as oxalate, malonate, glyoxylate, acetoacetate, ketomalonate, nirilotriacetate, and 
pyruvate can serve as a synergistic anion to form a ternary Fe-anion-Tf complex.  It was 
concluded that all synergistic anions must have a carboxylate group and a proximal 
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electron donor group.  An interlocking sites model for metal and anion binding was 
proposed in which a carboxylate group of the anion bridges the positively charged groups 
on the protein and the proximal functional group binds to the metal (38).  Furthermore, 
the carboxylate could have one substituent at the carbon α to the carboxylate, but 
disubstitution at the α-carbon negated the formation of a Fe-anion-Tf ternary complex, 
presumably due to unfavorable steric effects.  These non-physiological ternary complexes 
are typically quite weak.  Oxalate was the only anion that formed a complex with stability 
comparable to the Fe-carbonate-Tf complex (38). 
 Inorganic anions such as sulfate, sulfite, nitrate, nitrite, borate and phosphate, 
which have similarities with carbonate with respect to size, structure, charge, hydrogen 
bonding and ability to function as ligands for the transition metal ion, were also selected 
for synergistic anion replacement studies (38).  There was no evidence for the formation 
of an Fe-anion-Tf ternary complex with any of these anions, and it was concluded that 
inorganic anions do not substitute for carbonate. Hence all these anions were classified as 
nonsynergistic anions. 
 
1.4.2. 
Binding of anions to apotransferrin 
 In the 1980s, it was reported that the binding of anions to apoTf could be 
monitored by using difference UV spectroscopy (39).  Anion-binding equilibrium 
constants were measured by direct titrations of apoTf with a series of anions, which 
produce a negative peak at 245 nm in the UV spectrum.  Studies on a series of inorganic 
anions showed that the binding of bicarbonate to apoTf in the absence of iron is relatively 
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weak.  Divalent anions such as sulfate and HPO42- bind more strongly to apoTf, but the 
resulting binary anion-Tf complex is not capable of binding iron.  Among the inorganic 
anions that have been studied to date, only carbonate gives a binary species capable of 
binding iron.  Dicarboxylates were also evaluated for their binding with apoTf and were 
found to have binding constants 1 log unit smaller than those for diphosphonates (40).  
On the basis of the binding constants, the binding strength of anions to transferrin has 
been assigned in the following order:  PPi > other phosphonates > phosphate > sulfate > 
bicarbonate > chloride > perchlorate. 
 Studies on the mutants K206A, K296A, and R124A of the N-lobe transferrin have 
indicated that anions bind in the interdomain cleft of apoTf (41).  Another 
crystallographic study on apo-ovotransferrin in the presence of ammonium sulfate shows 
the binding of two sulfate anion within the cleft, indicating the presence of two sulfate 
binding sites (25). 
 EPR studies of iron transferrin complexes were conducted with 18 different 
anions, which were divided into three groups: 1) carboxylates with a proximal polar 
group, 2) dicarboxylates with an additional polar group and 3) dicarboxylates or 
carboxyamides (42).  The results produced a modification in the Schlabach and Bates 
model (38) for the mode of anion binding.  These studies proposed a model in which the 
synergistic anions bind as bidentate ligands, with coordination of both carboxylate and 
proximal groups.  This bidentate coordination of the anion to the iron is consistent with 
carbonate, dicarboxylate anions and other difunctional anions (42). 
 The addition of anions to diferrictransferrin does not produce a difference UV 
spectrum, presumably because the Fe3+ ion is coordinated to the two tyrosine residues 
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that are responsible for the difference UV spectrum of the anion-apoTf binary complex 
and blocks anion binding at this site.  However, the binding of anions to diferric Tf has 
been detected by EPR difference spectroscopy (43).  These studies presented a 
mathematical model and proposed the paired binding of anions to the protein i.e. four 
anions bind to diferric Tf, two in each lobe, with positive cooperativity. 
 The overall association constant for anion binding to diferric transferrin followed 
the sequence thiocyanate > perchlorate > pyrophosphate > adenosine triphosphate > 
chloride >> tetrafluoroborate, orthoborate, adenosine monophosphate, fluoride, sulfate 
and bicarbonate (43).  This series resembles the lyotropic series, (44;45) which is an 
arrangement of salts, anions or cations in ascending order of their effect on certain 
physical properties of proteins, with  F- <  SO42- <  HPO42- <  CH3CO2- <  Cl-  <  Br- <  
NO3-  <  I-  <  CCl3CO2-  <  ClO4-  <  SCN-. 
 
1.5. 
Transferrin and transferrin receptor mediated endocytosis 
 Transferrin delivers iron into cells via receptor mediated endocytosis (46;47).  
Transferrin receptors are present on the outer surface of the cells and are selective for 
diferric transferrin (48-50).  As the iron-loaded transferrin binds to the receptor, the 
transferrin receptor complex is internalized by clathrin coated pits, which form endocytic 
vesicles, as shown in Figure 1.7.  An ATP driven pump lowers the pH of the endosome to 
5.5 (51;52).  This acidic environment facilitates the dissociation of iron from the 
transferrin, (47) which may also involve the reduction of Fe3+ to the more weakly bound 
Fe2+ (53).  The iron is released into the cytoplasm and moved to mitochondria for heme 
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most often associated with a family of genetic disorders (referred to collectively as 
hereditary haemochromatosis) that lead to excessive iron uptake from the diet (3;56).  
  Most cases of hereditary haemochromatosis result from mutations in the 
regulatory protein HFE.  The most common mutations in HFE are C282Y and H63D.  A 
patient homozygous for the C282Y mutation will accumulate excessive levels of iron.  
The second mutation, H63D, is comparatively less prevalent, but when present in the 
heterozygous state along with the C282Y mutation, will also lead to haemochromatosis. 
(57-60). 
 The excessive uptake of iron observed in primary haemochromatosis is linked to 
the dysregulation of hepcidin, a 25 amino acid antimicrobial peptide that plays a central 
role in the regulation of iron homeostasis (61).  Hepcidin binds to and regulates 
ferroportin, a membrane-bound protein that transports iron from intestinal mucosal cells 
into the blood (62-64).  Mutations in HFE result in low levels of hepcidin in plasma, 
which allows increased iron uptake by ferroportin from intestines and leads to increased 
iron levels in the liver and other tissues (61). 
 The most common procedure for treating primary iron overload is therapeutic 
phlebotomy (3;65;66).  The removal of a unit (400-500 ml) of blood from the patient 
removes about 250 mg of iron, and this treatment continues till the normal serum ferritin 
(30 μg/l) and transferrin saturation (less than 30%) levels are reached (67).  Typically the 
removal of 2-4 units of blood per year will maintain overall iron balance (3;66).  
 There are other genetic disorders such as β-thalassemia that lead to severe anemia.  
Regular blood transfusions are required to treat the anemia, but this process bypasses the 
normal intestinal regulation of iron uptake (3).  Thus the patient becomes severely iron-
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.16 
 
16 
 
overloaded from the iron entering the body via transfusion.  This is referred to as 
secondary iron overload (68;69).  Secondary iron overload, if untreated, can be fatal. The 
widely accepted treatment is to couple the transfusions with the use of chelating agents to 
remove iron, a process known as chelation therapy (68;70-72).  Iron chelation therapy 
has been employed for over 50 years, and there has been extensive research in this area, 
with investigators searching for new synthetic compounds and performing various 
clinical studies characterizing the long term effects of known and new chelating agents.  
The following section describes existing and new ligands used in chelation therapy. 
 
1.7. 
Ligands for chelation therapy 
Desferrioxamine B (DFO, Desferal) is a trihydroxamate microbial iron transport 
agent produced by Streptomyces pilosus (73).  The structure of DFO is shown in Figure 
1.8. This naturally occurring siderophore binds to iron(III) in 1:1 ratio with a stability 
constant of 1030.6 , but it has a much lower affinity for other biological metal ions such as 
calcium and zinc (74).  DFO has been used as an effective chelator since the 1970s and is 
clinically approved for iron chelation therapy. 
In spite of being the most widely used iron chelator for the past 40-50 years, DFO 
has some disadvantages.  DFO is not orally active and is rapidly metabolized in the body 
(75), hence it must be administered subcutaneously or intravenously by slow infusion 
pumps (76).  The long infusion time of 8-12 h a day for 5-6 days a week leads to poor 
patient compliance (76;77).  In addition this treatment is expensive, which limits its 
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availability to patients worldwide (78).  To overcome these disadvantages, there is an 
extensive area of research focused on the development of orally effective iron chelators. 
 
 
 
 
 
 
 
Figure 1.8.  Structure of desferrioxamine B (DFO) 
 
An effective chelator for ferric ion must have a high stability constant as well as 
rapid complexation kinetics (73;79).  In addition, a chelator should possess in vivo 
efficacy and low toxicity (73).  Ligands with structures similar to the siderophores and 
other strong binding ligands are under investigation for the replacement of DFO.  The 
search for improved, orally effective chelators has led to the rediscovery of old ligands, 
like N, N’-bis(2-hydroxybenzyl)ethylenediamine-N,N’-diacetic acid (HBED) and 2-
pyridylcarboxaldehydeisonicotinoylhydrazone (PCIH) (78).  HBED has an affinity 
constant of 1039.6 for iron(III) and has a low affinity for other metal ions (77).  HBED and 
dimethyl-HBED have been reported to be non-toxic in some animal studies and are under 
further clinical investigations (80). 
Deferiprone (L1, Ferriprox), shown in Figure 1.9, is a prospective ligand for iron 
chelation therapy that has been under investigation for many years (71;81;82).  Unlike 
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the hexadentate DFO molecule, L1 acts as a bidentate ligand via the 3-hydroxy and 4-
keto functional groups and forms a stable FeL3 complex (83). 
 
 
 
 
 
 
 
Figure 1.9.  Structure of Deferiprone (L1)  
 
 The hydroxypyridinone (HOPO) functional group of L1 offers many of the same 
advantages as the hydroxamate group of DFO.  This group binds strongly and selectively 
to high-valent metal ions like Fe3+, with weaker binding to essential transition metal ions 
such as Zn2+, and almost no binding affinity for Ca2+  (74).  Moreover, as a neutral low-
molecular-weight compound, it is well absorbed from the gut (84).  Initial clinical studies 
reported concerns over its long term safety due to several side effects, such as 
neutropenia, agranulocytosis, zinc deficiency, and gastrointestinal disturbances (71;76).  
A case of progressive hepatic fibrosis was also reported (81), and this complication is still 
controversial.  With more studies reported (82;85), a safety profile has been established 
for deferiprone, with certain guidelines to monitor during therapy (86;87).  The 
disadvantages of deferiprone therapy are that not all patients reach negative iron levels 
and the need for a weekly blood count due to the risk of agranulocytosis (71;87).  
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Combined chelation therapy using DFO and L1 has also been reported (88), and the 
preliminary studies suggest that this can be a potential new approach to treat iron 
overload (78;85). 
 The HOPO group has been incorporated into hexadentate ligands by both Hider 
and Raymond (89-92). The ligands N,N,N-tris[2-(3-hydroxy-2-oxo-1,2-
dihydroxypyridin-1-yl)-acetamidoethyl]amine (CP130) (93) and TREN-(Me-3,2-
hydroxypyridonate), TREN HOPO (94) have been prepared as both 3-hydroxy- and 1-
hydroxypyridin-2-ones respectively.  The hexadentate ligand TREN-(Me-3,2-
hydroxypyridonate) has shown promising results in rat studies compared with its 
bidentate counterparts (91), but as yet there is no success in chelation therapy. 
 In the meanwhile a new orally active iron chelating agent deferasirox (ICL670A) 
(95) has been developed by Novartis and is available for use in the United States (87).  
Deferasirox is 4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid, as shown in 
Figure 1.10 (96).  It is a tridentate chelator and binds iron(III) in a 2:1 ratio (76).  It has 
been approved for the treatment of chronic iron overload in patients from the age of 2 
years and older (87).  Deferasirox can be easily administered orally once a day and has 
shown equivalency with desferrioxamine at high dosages (76;87;97).  Due to the limited 
long term data, several questions may arise in terms of its effectiveness and safety.  
Further studies will determine the overall success of deferasirox.  In the meanwhile more 
promising chelators are being synthesized.  One such chelator, deferitrin, belongs to the 
ferrithiocin class of chelators and is undergoing preliminary trials (87;98;99). 
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Figure 1.10.  Structure of Deferasirox 
 
 Historically, chelation therapy has targeted the large amounts of iron stored 
intracellularly as a complex with the iron storage protein ferritin (100;101).  Ferritin 
consists of 24 subunits which pack together to form a hollow sphere (3).  The iron is 
stored in the interior of this sphere, and is physically inaccessible to most chelating 
agents.  As a result, removing iron from ferritin is extraordinarily difficult (100).  The 
most effective approach is a two-step process.  The ferritin is incubated with a mixture of 
the chelating agent and a small reducing agent.  The reducing agent is small enough to 
enter the protein shell and reduce the ferric ion to soluble ferrous ion, which then diffuses 
out of the protein and is captured by the chelating agent (102;103). 
 The iron in transferrin is a much more accessible target, as it is present in the 
serum, circulating freely in the body.  In addition, by maintaining a low level of iron-
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saturation for serum transferrin, one can avoid the oxidative damage from non-
transferrin-bound-iron that is usually seen when iron overload leads to saturation of the 
transferrin binding capacity (104).  The direct loss of iron to a chelator seems to be the 
most likely mechanism of iron release, but this process tends to be quite slow (7).  Hence 
the need to study the kinetics of iron removal from transferrin. 
 
1.8 
Kinetic mechanisms for iron release 
 Iron release from transferrin is studied by monitoring changes in the spectral 
properties of the protein.  The kinetic assays are most commonly done on a Uv-vis 
spectrophotometer or a fluorimeter.  The paramagnetic ferric ion in holotransferrin 
quenches the intrinsic fluorescence of the protein, so that iron release results in an 
increase in fluorescence intensity (105).  Whereas the absorbance in the ultraviolet and 
visible spectra increases due to the charge transfer band of the Fe(III) bound to the two 
tyrosine ligands, so on iron release there is a decrease in absorbance (105).  For kinetic 
studies, the rate of iron release can be determined by monitoring the increase in 
fluorescence intensity or the decrease in absorbance with time. 
 Iron release kinetics have been studied using a wide range of ligand types, 
including catechols (49;73;106-112), hydroxamates (107;113;114), hydroxypyridinones 
(111;114;115), phosphonates (116-127), and aminocarboxylates (128;129).  Early studies 
examined iron release from diferric transferrin 
(73;79;113;116;118;119;121;126;130;131).  After methods were developed to prepare 
both forms of monoferric transferrin (C- and N-lobe) (120;121), most studies have used 
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one of the monoferric forms to avoid the complexity of the simultaneous release of iron 
at different rates from two sites.  The degree of cooperativity between iron release from 
the two sites has been examined by monitoring iron release from one site while the 
kinetically inert Co3+ ion occupies the other site (120;132).  Cooperativity has also been 
addressed by comparing iron release from N-lobe monoferric transferrin with iron release 
from the recombinant N-lobe half-transferrin molecule (120;132;133).  Most studies 
report rather limited cooperativity between the two sites (128;129;132;133). 
 Over the years several different mechanisms for iron removal from transferrin 
have been proposed (73;113;121;125;128;129;134).  These mechanisms are based on the 
kinetic order of the iron removal reaction with respect to the ligand concentration.  The 
exact mechanism of iron release is not yet determined.  In general there is a consensus 
that iron removal kinetics from transferrin fall into three categories: saturation kinetics, 
first order kinetics and complex kinetics (a combination of first order and saturation 
kinetics) as shown in Figure 1.11.  The following sections describe the development of 
various mechanisms for iron release, with an emphasis on certain factors such as the 
binding of allosteric anions, which influences the iron release kinetics. 
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Figure 1.11.  Simulated plots of kobs versus ligand concentration that illustrate 
saturation, first order and complex kinetics 
 
1.9. 
Early iron release studies 
 The initial studies on iron removal from diferric transferrin were performed in the 
1970s by using chelators like nitrilotriacetic acid (NTA), citrate and 
ethylenediaminetetraacetate (EDTA) (126;135).  Egyed studied iron removal using 
physiological ligands such as adenosinetriphosphate (ATP), which might be involved in 
intracellular iron release (127).  Around the same time two groups reported the 
percentage of iron removal from transferrin by various chelating agents.  Pollack et al. 
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(131) performed iron removal from transferrin by using mixtures of the strong chelator 
desferrioxamine (DFO) with various weak chelators and anions that facilitate the transfer 
of iron from transferrin to DFO.  Morgan investigated the ability of various cellular 
metabolites to release iron from transferrin on the basis of the rate at which they could 
transfer iron between rabbit transferrin and human apotransferrin.  Pyrophosphate 
removed the maximum amount of iron, followed by ketomalonate, NTA, ATP and citrate 
(126).  Some of these anions are also effective chelators (anionic ligands), and iron 
removal of these anionic ligands was also evaluated in the absence of DFO (126).  
Different trends were seen in the results.  
 Ligands also affect the rate of exchange of the synergistic carbonate anion.  Aisen 
et al. (20) proposed that the ligands served as a temporary substitute for the carbonate, as 
shown in Figure 1.12. 
 
 
* 14C 
 
Figure 1.12.  Carbonate exchange mechanism (20) 
 
 The effect of adenosine nucleotides and pyrophosphate (PPi) on the exchange of 
transferrin bound carbonate was investigated by Egyed (127).  The exchange of carbonate 
in the ternary complex of transferrin was accelerated by adenosine triphosphate (ATP), 
adenosine diphosphate (ADP) and PPi, while adenosine monophosphate (AMP), cyclic 
AMP and phosphate had no effect.  ATP has been proposed to accelerate carbonate 
FeTfH*CO3 + A- FeTfA + H*CO3-
FeTfA + HCO3- FeTf HCO3- + A-
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exchange but does not remove any iron, and PPi was proposed to replace the anion as 
well as remove iron from the ternary complex. These studies also proposed two 
mechanisms explaining how ATP, as opposed to PPi, is found within the endosome and 
might play a direct role in intracellular iron release. 
 Morgan investigated the effect of several phosphate compounds and iron chelators 
as mediators of iron release and also studied the effect of hydrogen ion concentration on 
iron release (135).  The rate of iron release was accelerated in the presence of several 
mediators and also with an increase in the hydrogen iron concentration.  Morgan’s work 
with mediators at high concentration indicated the presence of saturation kinetics.  A two-
step reaction mechanism was proposed.  The first step involved labilization of the iron by 
the interaction of hydrogen ion with the transferrin-iron-anion complex.  The second step 
involved the release of iron from the transferrin by the mediator, forming a complex to 
facilitate the transfer of iron to the passive iron acceptor ligand, DFO (135). 
 
1.10. 
Saturation kinetics and its development 
 In the late 1970s Raymond and co-workers (73) began studies on iron release by 
synthetic catechols (3,4-LICAMS and MECAM), which were based on the structure of the 
siderophore enterobactin, a naturally occurring iron chelator.  A hyperbolic dependence 
of the rate on the chelator concentration was observed.  Carrano and Raymond (73) 
proposed a pre-equilibrium mechanism, which predicts the formation of a ternary 
intermediate consisting of Fe3+, transferrin (Tf) and the competing ligand [L].  In the rate-
limiting step, this ternary intermediate dissociates to release the iron from transferrin.  
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FeTf + L LFeTf FeL + Tf
This mechanism was consistent with the observation of saturation kinetics, but there was 
no direct evidence of the formation of the proposed ternary intermediate complex. 
 
 
Figure 1.13.  Pre equilibrium mechanism for iron release from transferrin  
 
 Cowart et al. (113) investigated the release of iron by AHA and also observed 
saturation kinetics.  However, they also studied the donation of iron from the Fe(AHA)3 
complex to apoTf.  These studies on iron donation allowed them to characterize the 
spectrum of an Fe-AHA-Tf intermediate.  This intermediate was not formed to a 
detectable level during iron removal, which eliminated Raymond’s pre-equilibrium 
mechanism.  They proposed a new mechanism as shown in Figure 1.14. 
 According to Cowart et al. (113), the observed saturation kinetics reflect the 
presence of a rate-limiting conformational change in ferric transferrin from a closed to an 
open form as shown in step 1 of Figure 1.14.  Once the protein is in the open form, the 
incoming ligand binds to the iron and forms a quaternary complex L-Fe-CO3-Tf, which 
then falls apart to release iron from the transferrin.  In the closed conformation, the iron is 
well shielded from the incoming ligand.  Thus the ligand can remove iron only when the 
protein is in the open conformation.  At high concentrations of the ligand, i.e. under 
saturating conditions, the rate constant for iron release corresponds to the forward rate 
constant (k1) for the conformational change from the “closed” native form to the “open” 
more reactive conformation of transferrin.  The Bates mechanism is further supported by 
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[L]kk
d
max
obs +=
the crystal structures of the ‘closed’ ferric transferrin and the ‘open’ apotransferrin form 
of the protein (26;28;30;136). 
 
 
 
 
 
 
*Open conformation 
 
Figure 1.14.  Bates conformational change mechanism (113) 
 
 Ligands like acetohydroxamic acid (AHA) (113;114), 3,4-LICAMS (109), 
enterobactin (73), and 1,2-dimethyl-3-hydroxyl-4-pyridinone (L1) (114) show saturation 
kinetics with respect to the free ligand concentration.  On the basis of this mechanism, the 
ligand dependence of the observed rate constant for iron removal is given by the equation 
(1.1), 
                                                                                                                      (1.1)         
 
where, kmax is the rate constant under saturating conditions and kd is a kinetic parameter 
corresponding to the ligand concentration at half saturation.  If kmax simply represents the 
rate constant for the conformational change of the transferrin, then the rate should be 
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independent of the nature of the ligand.  Studies have shown that many ligands have 
similar values for kmax, but there are significant deviations (114;120;128;129;132;137). 
 
1.11 
Effect of anions on iron release 
 Various salts of nonsynergistic and non-chelating anions (e.g. Cl- and ClO4-) have 
been shown to affect the rates of iron release from transferrin (114;138;139).  These 
anion effects have been studied extensively, but with rather confusing results.  Some 
anions increase the rate of iron release, some decrease the rate of iron release, and some 
have no effect.  The effect also varies between the C- and N-lobes of the protein.  For 
example, perchlorate accelerates the rate of iron removal from the C-lobe, but retards iron 
removal from the N-lobe (138). 
 The anion effect can also depend on the chelating agent that is being used to 
remove the iron.  At pH 7.4 chloride increased the rate of iron release from C-terminal 
monoferric transferrin by EDTA, but retarded iron release from N-terminal monoferric 
transferrin (138;140).  In other studies at the same pH, chloride accelerated the iron 
release by citrate (134), AHA (114) and L1 (114) from both C-terminal Tf and N-
terminal Tf.  When used in the presence of PPi, Cl- increased the rate of iron release from 
C-terminal monoferric Tf but had no effect on the rate of iron release from N-terminal 
monoferric Tf at pH 7.4 (117;123). 
 The anion studies suggested that binding of an anion to the protein can either 
increase or decrease kmax, depending on the specific combination of anion and ligand 
(134;138).  It was proposed (134) that there is an allosteric Kinetically Significant Anion 
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Binding (KISAB) site, which is likely to play an important role in iron release kinetics.  
Raymond and coworkers (107) studied the rate of iron release by LICAMS as a function 
of the chloride concentration and concluded that the KISAB site must be occupied by an 
anion for any iron release to occur.  Site directed mutagenesis (75;141) and 
computational studies (142) have attempted to locate the KISAB site, but the exact 
location is still unclear. 
 In the closed structure of the transferrin N-lobe, Lys-206 and Lys-296, form a 
hydrogen bond which appears to help link the two N-lobe domains in the closed form of 
the protein.  The presence of the hydrogen bond indicates that the two lysines share a 
single proton (143).  It has been suggested that the addition of a second proton to this pair 
to form two charged lysine side chains would favor the open protein conformation, and 
thus could play a critical role as a trigger for iron release (75).  Site directed mutagenesis 
on the recombinant N-lobe half-transferrin molecule (hTf/2N) has confirmed that 
mutation of either of the lysines to alanine, glutamate or glutamine dramatically slows 
down the rate of iron release (75;141). 
 
1.12. 
First order and complex kinetics  
 The original Bates mechanism (113) was consistent with iron release by ligands 
such as AHA and LICAMS, but subsequent studies have identified a variety of ligands 
that do not follow simple saturation kinetics with respect to the free ligand concentration.  
The aminocarboxylate ligands, nitrilotriacetic acid (NTA) (129) and 
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diethylenetriaminepentaacetic acid (DTPA) (128) show simple first order kinetics with 
respect to the ligand concentration. 
 Ligands like PPi (117;119-122;125) and aminophosphonic acids 
(117;119;121;128;129) follow complex kinetics, which is a combination of saturation 
and first order kinetics.  At low concentrations these ligands follow saturation kinetics, 
but at higher concentrations of the ligand, the rate constant shows a linear increase rather 
than reaching a plateau.  These complex kinetics can be described by equation (1.2). 
 
                                                                                                                                 (1.2) 
 
1.13 
Proposed mechanisms to explain complex kinetics 
 Three mechanisms have been proposed to explain complex kinetics.  The physical 
significance of the rate parameters in equation (1.2) depends on the mechanism. 
1.13.1 
Bertini’s mechanism  
 Bertini and co-workers (125) observed complex kinetics for iron release by PPi.  
They attributed the saturation component to the Bates conformational change mechanism 
and proposed that the linear increase in the rate constant at high ligand concentration is 
due to the binding of the anionic PPi ligand to an allosteric binding site (the KISAB site) 
on the protein, as shown in Figure 1.15. 
 
 
][' Lk
[L]k
[L]kk
d
max
obs ++=
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Figure 1.15.  Bertini’s mechanism for iron release by PPi (125) 
 
The { } brackets are used to indicate the binding of the anionic ligand to an allosteric site 
on the protein.  In this mechanism, there are two saturation pathways one with the 
KISAB empty and one with the KISAB site occupied by the anionic ligand.  In order to 
explain the linear increase at higher ligand concentration, it is necessary to assume that 
ligand binding to the KISAB site is far from saturation.  
 
1.13.2 
Egan’s mechanism 
 According to Egan’s model (123;134) there is no saturation component at all.  
Instead, he proposes that iron release takes place by two first order pathways, one fast 
and one slow, which are linked by an anion binding equilibrium.  The representation of 
the Egan’s model is shown in Figure 1.16, where the { } brackets represent the KISAB 
site. 
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Figure 1.16.  Egan’s mechanism for iron release 
 
At low ligand concentration, the KISAB site is occupied by the anion from the buffer or 
from the added salts, while at high ligand concentrations, the ligand competes with the 
anion to occupy the KISAB site.  Under these conditions, kobs is defined by the equation, 
 
݇௢௕௦ ൌ
ሺ݇ଵሾܮሿ ൅ ݇ଶܭ௘௤′ሾܮሿଶ ሻ
ሺ1 ൅ ܭ௘௤′ሾܮሿሻ
 
 
(1.3)
ܭ௘௤ ൌ
ሾሼܮሽܨ݂݁ܶሿሾܣሿ
ሾሼܣሽܨ݂݁ܶሿሾܮሿ
 
(1.4)
ܭ′௘௤ ൌ
ܭ௘௤
ሾܣሿ
 
(1.5)
 
Egan accounts for the downward curvature in the plot of kobs versus ligand concentration 
as a consequence of the fact that k2 < k1.  In order to account for simple saturation 
kinetics, one would have to assume that k2 is essentially zero. 
 
FeTf{A-} Products
Keq[L] {A
-}
FeTf{L}
k2[L]
k1[L]
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1.13.3 
Harris’ mechanism for iron release  
 Harris and co-workers accepted the Bates mechanism for the saturation 
component (116;119;132).  Since neutral ligands tended to follow saturation kinetics, 
while anionic ligands often followed complex kinetics, they proposed that the first order 
component represents a separate reaction pathway for iron release that involves the slow 
replacement of the synergistic carbonate anion by the incoming ligand, followed by the 
rapid dissociation of ternary Fe-L-Tf complex (116;132), as shown in Figure 1.17.  
 
 
 
 
Figure 1.17.  Proposed mechanism for first-order component of iron removal  
 
 If a ligand can function as a suitable replacement for the synergistic carbonate 
anion, then it can follow this pathway for iron release.  Ligands like NTA (129) show 
simple first order kinetics and appear to utilize this pathway exclusively, while ligands 
like pyrophosphate (PPi) (119;129), and N,N-bis(phosphonomethyl)glycine (DPG) 
(119;129) show complex kinetics, which indicates that they use both the conformational 
change and carbonate substitution pathways to release iron from transferrin. 
 Iron release by phosphonoacetic acid (PAA) has been studied extensively in our 
lab (137;144).  The rate of iron release was shown to slow down with the elongation of 
the ligand and with disubstitution at the central methylene group of PAA.  The half lives 
Fe-CO32--Tf + L Fe-L-Tf + CO32-
Fe-L-Tf apo-Tf + Fe-L
slow
fast
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of iron removal by PAA, monobenzyl and dibenzyl derivatives of PAA were measured, 
and it was found that the half life of iron release increased from 20 min for PAA to 30 
min for the monobenzyl PAA to more than 600 min for dibenzyl PAA (137).  This 
pattern is consistent with the early studies that established structural criteria for 
compounds that are able to substitute for the bicarbonate synergistic anion (38).  For 
example, glycolate and lactate can both substitute for carbonate.  But the addition of a 
second methyl substituent to form methyllactate destroys the ability to substitute for 
carbonate. 
 Other evidence in support of this model comes from a study which involved iron 
release by pyrophosphate (PPi) and tripolyphosphate (TPP) (137).  Iron release by PPi 
follows complex kinetics, whereas iron release by TPP follows simple saturation kinetics.  
It was proposed that the first order component is not seen with the longer TPP because 
the additional phosphate group prevents this compound from replacing the synergistic 
carbonate anion (137).  PPi and PAA can form six membered chelate rings and are 
expected to serve as synergistic anions (137;144).  The presence of a first order 
component for PPi and PAA further supports the hypothesis that the ability to function as 
a synergistic anion is a key requirement for a ligand to remove iron via the first order 
pathway. 
 Most of the groups agree that a conformational change of the protein is required 
for the incoming ligand to access the iron binding site of the transferrin using the 
saturation pathway.  The first-order pathway that some ligands can use still needs to be 
characterized more clearly.  It is likely that iron removal kinetics follows a combination 
of more than one mechanism. 
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1.14 
Variation in kmax  
 According to the Bates conformational change mechanism, as discussed in section 
1.10, kmax, the maximum rate constant, is the forward rate constant for the conformational 
change from the close to the open form of ferric transferrin as shown in Figure 1.5.  This 
conformational change occurs prior to any interaction with the ligand, and thus the value 
of kmax for all ligands should be the same.  However this is not the case.  The kmax values 
for iron removal from both the C-terminal and N-terminal sites vary by about an order of 
magnitude for the ligands that have been studied to date (128;144).  This assessment 
excludes the results for iron release by NTA and DTPA, which show kmax values of zero 
(128;129). 
 Can this variation in kmax be linked to the anionic effects ?  As discussed in earlier 
sections, anions are known to alter the rate of iron release by binding to the allosteric 
KISAB site.  Raymond and co-workers have proposed the absolute requirement of some 
sort of anion binding for the conformational change to occur followed by iron release 
(107;110).  Zak  et al. (145) have proposed that anionic ligands are in competition with 
inorganic anions such as chloride to occupy KISAB site.  The anion effects are 
inconsistent, as some anions increase the rate of iron release and some decrease the rate 
of iron release.  Thus anion effects might either increase or decrease the kmax value. 
 Our group speculates that the variation in kmax might reflect the binding of anionic 
ligands to the allosteric KISAB site (137;144).  In this model, an anionic ligand might 
self-regulate the rate of iron release by binding to the KISAB site in addition to chelating 
the iron.  We are also interested in the extent to which anion binding alters the rate of iron 
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removal through the proposed first order pathway.  To address these issue, we have 
chosen a set of reference ligands, consisting of AHA and L1, which show simple 
saturation kinetics (113;114), and NTA and DTPA, which show simple first order 
kinetics (119;128;129).  We have evaluated the impact on iron release by these reference 
ligands from the addition of simple, non-chelating anions as well as the addition of 
chelating anions. 
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Chapter 2 
 
Materials and Methods 
 
 This chapter provides detailed information about the methods and materials 
required during the course of the studies on the kinetics of iron release.  The preparation 
of proteins, along with the techniques used to quantify the proteins, such as 
spectrophotometry and electrophoresis, are included.  The solutions of ligands and 
buffers used during the kinetic studies of iron release are listed. This chapter also 
discusses the spectroscopic methods, such as Uv-vis spectroscopy and fluorescence 
spectroscopy that were used to follow iron removal from transferrin. 
 All solutions were prepared by using Millipore MilliQ water.  This system 
purifies the building deionized water further to remove any organic and inorganic 
contaminants to give a resistance of 18 mΩ cm-1.  The experiments done during this study 
involve transferrin, a high-affinity Fe(III)-binding protein, and other chelators.  Hence it 
was important to maintain metal free conditions.  All glassware and containers used 
during the course of the study were soaked in acid overnight and then washed thoroughly 
with Millipore water. 
2.1  
Preparation of solutions 
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2.1.1 
Preparation of HEPES buffer  
 N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) was the buffer 
used in all studies. A 0.1 M solution was prepared by dissolving 23.83 g of HEPES in 
Millipore water and adjusting the pH to 7.4 by the addition of concentrated sodium 
hydroxide solution. The pH was confirmed after a final dilution to one liter.  The pH was 
monitored with a Fischer accumet 25 pH meter equipped with a combination electrode 
that was calibrated with pH 7.0 and pH 4.0 buffers.  The pH of the buffer solution was 
monitored on a daily basis before starting the kinetic experiments. 
2.1.2 
Preparation of HEPES and sodium perchlorate buffer 
 A buffer solution of 0.1 M was prepared by dissolving 12.24 g of sodium 
perchlorate (NaClO4) and 23.83 g of HEPES in Millipore water.  The final dilution was 
made to one liter and the pH was adjusted to 7.40. 
2.1.3 
Preparation of iron solutions 
 Ferric ion stock solutions were prepared by dissolving solid ferric chloride in 
standardized 0.1 M nitric acid.  The final concentration of the ferric ion was determined 
by complexometric titrations with EDTA (1).  The stock solution is stable due to the low 
pH, which prevents hydrolysis of the ferric ion. 
 Ferric nitrilotriacetic acid (Fe(NTA)23-) was prepared by adding 2 equivalents of 
NTA to a known quantity of ferric ion and diluting to volume.  The final pH of these 
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solutions was approximately 3.  All solutions of the Fe(NTA)2 were freshly prepared to 
avoid the slow hydrolysis of the ferric ion. 
2.1.4 
Preparation of ligand solutions  
 The ligands used in this study were commercially available as high-purity 
compounds.  Acetohydroxamic acid (AHA), phosphonoacetic acid (PAA), sodium 
methanesulfonate (SMS), 3-phosphonopropionic acid (3-PPA), N-
(phosphonomethyl)iminodiacetic acid (PIDA),  methylenediphosphonic acid (MDP),  
nitrilotriacetic acid (NTA),  diethylenetriaminepentaacetic acid (DTPA) and 2,3-
dihydroxypyridine (2,3-DHP) were purchased from Sigma Aldrich.  Methylphosphonic 
acid (MPA) and the dipotassium salt of methane disulfonic acid (MDS) were purchased 
from Fluka.  The disodium salt of 1,2-ethanedisulfonic acid (EDS) was purchased from 
Eastman Kodak company.  1,2-Ethylene diphosphonic acid (EDP) was purchased from 
Lancaster.  1,2-Dimethyl-3-hydroxy-4-pyridone (L1) was purchased from Acros 
Organics.  5-Chloro-2,3-dihyroxypyridine was purchased from Alfa Aesar.  
Phosphonoacetaamide (PAM) and 1-methyl-3-hydroxy-2-pyridone (3HMPY) were 
prepared at UMSL by Dr. Spilling’s group.  The ligand stock solutions were prepared in 
0.1 M HEPES buffer and adjusted to pH 7.4.  
2.2 
Preparation, purification, confirmation and quantitation of proteins  
 The iron free (apo) and diferric (holo) forms of human serum transferrin were 
purchased from Sigma Aldrich.  The commercially available apo and holo transferrin 
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were further purified to remove low-molecular-weight (LMW) components.  All the 
absorbance measurements were recorded by CARY 100 Bio Uv-vis spectrophotometer.   
2.2.1 
Purification of Apotransferrin 
Apotransferrin was purified by following literature procedures (2).  
Approximately 200 mg of solid apotransferrin was dissolved in 8 ml of 0.1 M HEPES/ 
perchlorate buffer at pH 7.4.  The apotransferrin solution was then transferred to a 10 ml 
Amicon ultrafiltration cell fitted with an XM-50 filter membrane, which has a molecular 
weight cut off filter of 50 kDa.  As the name suggests, this membrane retains the protein 
but allows small chelates and inorganics to be removed.  The stirrer was then set to a 
relatively slow speed, and a pressure of about 60 psi N2 was applied to the Amicon cell to 
force buffer through the filter and reduce the volume to 1 ml.  The cell was refilled with 
0.1 M HEPES 6-8 times to ensure complete removal of perchlorate.  The final 
concentrated protein was transferred to a small vial through a syringe filter to remove 
debris that accumulates in the solution during ultrafiltration.   
The UV-vis spectrum of the apotransferrin was recorded between 240-600 nm on 
a Cary 100 spectrophotometer.  A baseline for 0.1 M HEPES was recorded and stored.  
The protein concentration was determined by diluting 50 μl of protein in 1000 μl of 0.1 
M HEPES buffer.  A protein spectrum was recorded as shown in Figure 2.1.  A single 
protein peak at 278 nm was observed.  The molar extinction coefficient at 278 nm of 
93,000 M-1cm-1 (3) was used to determine the apotransferrin concentration for the dilute 
solution, and appropriate dilution factors were used to calculate the exact concentration 
for the concentrated apotransferrin stock solution.  The sample was confirmed to be iron 
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free by the lack of a Fe-protein charge-transfer peak at 465 nm and also by using urea-
PAGE electrophoresis as described in the following section. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.   UV-vis spectrum of apotransferrin in 0.1 M HEPES buffer at pH 7.4. 
The baseline trace for 0.1 M HEPES is shown in red.  The trace in brown color is for 
the 50 fold dilution of the stock apotransferrin. 
 
2.2.2 
Preparation of Diferric (Holo) transferrin 
Approximately 200 mg of solid diferric transferrin was dissolved in 8 ml of 0.1 M 
HEPES/perchlorate buffer at pH 7.4.  The protein solution was transferred in a 10 ml 
Amicon ultrafiltration cell fitted with a XM-50 filter membrane.  The protein was washed 
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with 0.1 M HEPES buffer 6-8 times to remove the perchlorate and any other low-
molecular-weight contaminants.  The UV-vis spectrum of diferric transferrin is shown in 
Figure 2.2, with the protein peak in the UV range and the Fe3+-tyrosine charge transfer 
peak in the visible range.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  The UV-vis spectrum of diferric transferrin in 0.1 M HEPES buffer at 
pH 7.4.  The baseline trace for 0.1 M HEPES is shown in red.  The trace in purple is 
for the 50 fold dilution of the stock diferric transferrin.  The trace in green is for the 
undiluted stock solution of diferric transferrin.  
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 The protein concentration of the purified diferric transferrin was calculated from 
the UV-vis spectrum using a molar extinction coefficient of 113,000 M-1cm-1 at 278 nm 
(3).  The iron concentration was determined by using a molar extinction coefficient of 
5,000 M-1cm-1 at 465 nm (3).  The iron:protein ratio was estimated from the ratio of the 
concentrations of iron and protein.  Solutions with a ratio of 2.0 ± 0.05 were used in 
subsequent studies.  The purity of the diferric transferrin was also confirmed by urea-
PAGE. 
2.2.3 
Preparation of C- terminal monoferric transferrin 
 C-terminal monoferric transferrin was prepared from apotransferrin by the 
addition of one equivalent of Fe(NTA)2 following procedures in the literature (3;4).  It is 
well-established that NTA delivers Fe3+ selectively to the C-terminal binding site (3-5).  
A weighed amount of solid sodium bicarbonate corresponding to 5 mM was added to an 
aliquot of apotransferrin. The pH of the protein was adjusted to pH 6.0 and an Fe(NTA)2 
solution was added drop wise with constant stirring.  The solution was allowed to 
equilibrate for about 20 min.  
 The iron loaded protein was then washed extensively with 0.1 M HEPES buffer in 
an Amicon ultrafiltration cell fitted with an XM50 filter membrane to remove any traces 
of the NTA that was used for the delivery of the ferric ion to the protein.  The 
absorbances at 278 nm and 465 nm were measured, and the concentration of the protein 
and the ferric ion were determined using the extinction coefficients of 103,000  M-1cm-1  
and 2950 M-1 cm-1, respectively (3).  The percentage of transferrin binding sites occupied 
by iron was calculated from the iron and protein concentrations. The selective binding at 
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the C-terminal site was confirmed by using urea-PAGE electrophoresis discussed in 
detail in section 2.3. 
 
2.2.4 
Preparation of N- terminal monoferric transferrin 
 N-terminal monoferric transferrin was prepared from diferric transferrin by 
following a modified version of a literature procedure (3;4).  It is known from the 
literature that perchlorate accelerates iron removal by EDTA from the C-terminal site and 
retards release of iron from the N-terminal site (4).  One ml of diferric transferrin was 
added to 3 ml of 2.67 M sodium perchlorate and 0.134 M ethylenediaminetetraacetic acid 
(EDTA).  The removal of iron by EDTA was monitored by following the change in 
absorbance at 465 nm until the absorbance was 50% of the initial absorbance value.  The 
above solution was then transferred to an Amicon ultrafiltration cell and washed 6 times 
with 0.1 M HEPES buffer to remove the NaClO4, Fe-EDTA and free EDTA.  The 
concentration of the protein was determined from the absorbance at 465 nm using an 
extinction coefficient of 2150 M-1 cm-1 and at 278 nm with an extinction coefficient of 
103,000 M-1cm-1 (3).  The selective loading of iron into the N-terminal binding site was 
confirmed using urea-PAGE electrophoresis.  
2.3 
Urea-PAGE gel electrophoresis 
 Commercial tris-boric acid-urea (TBE) denaturing gels for the Protean 3 mini-gel 
electrophoresis cell were purchased from Bio-Rad laboratories.  The composition of the 
gels is 5% polyacrylamide-methylene-bis-acrylamide, 1.0-2.5% tris(hydroxylmethyl)- 
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aminomethane (tris), with 35-40% urea.  The gel was removed from the packaging, and 
the comb was removed carefully from the wells without causing any damage to the wells.  
The wells were then washed with Millipore water to ensure that they were free from any 
urea.  Protein samples were analyzed using a slight modification of the procedure 
published by Makey and Seal (6). 
2.3.1 
Solutions prepared for urea-PAGE electrophoresis 
 The TBE running buffer containing 89 mM tris base, 89 mM boric acid and 2 mM 
EDTA was prepared in Millipore water and adjusted to pH 8.3.  The TBE sample loading 
buffer containing 45 mM tris base, 45 mM boric acid, 1 mM EDTA, 3.5 M urea, 0.005% 
bromophenol blue and sucrose was prepared and stored at 4 ˚C.  A 0.27% solution of 
Coomassie blue R 250 in 500 ml methanol, 100 ml glacial acetic acid and 500 ml 
Millipore water was used as a staining solution.  The destaining solution was prepared by 
mixing 100 ml of methanol and 150 ml of glacial acetic acid, and diluting to a final 
volume of 2 L with Millipore water. 
 Samples were loaded with a 2-20 μl Eppendorf pipetter with a gel loading pipette 
tip attached to ensure the accurate loading on the gel.  The tip was disposed of after every 
loading to prevent contamination of the protein samples.  Each well on the gel was loaded 
with 5 μg of protein contained in a 10 μl sample volume.  The sucrose in the sample 
loading buffer holds the sample in the well until the electrophoresis is started.  A 1:1 ratio 
of loading buffer to transferrin sample was used.  The stock transferrin samples were 
stored in the refrigerator at 4 °C. 
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            Gels were run for 4.5 hours at a constant voltage of 100 V using a Biorad Model 
500/200 power supply.  The initial current was about 20 mA.  On completion of the run, 
the precast gel was removed from the mini protean electrophoresis cell, and the gel was 
carefully removed from the plastic plates.  The gel was stained by soaking in the staining 
solution for half an hour, followed by destaining.  The destaining solution was exchanged 
till the background color was removed and the bands were clearly visible on the gel.  
Once the gel was visibly destained, it was scanned on the Dell A920 scanner and the 
pictures were saved.  A typical Urea-PAGE gel is shown in Figure 2.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  5% TBE-Urea PAGE, with the characteristic bands for the four forms 
of transferrin denoted as ApoTf for apotransferrin, CTf for C-terminal monoferric 
transferrin, NTf for N-terminal monoferric transferrin and DiTf for diferric 
transferrin. 
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2.4 
Instrumentation 
The main emphasis of our research is the kinetics of iron release from transferrin 
protein by low-molecular-weight chelating agents.  These reactions can be monitored by 
following the changes in the Uv-visible or fluorescence spectrum of the protein (7). 
These changes are measured on the instruments listed below. 
2.4.1 
Uv-vis Spectrophotometer 
 Uv-vis absorbance spectra were measured on a dual beam Varian Cary 100 
spectrophotometer equipped with a temperature control accessory and a multicell holder 
transport accessory.  The Cary Win UV software was used to operate the instrument.  All 
experiments were carried out at 25 ◦C, pH 7.4 in 0.1 M HEPES.  A protein concentration 
of about 30 µM was used in the experiments. 
2.4.2 
Fluorescence spectrophotometer 
 Fluorescence spectra were recorded using a Jobin Yvon Horiba FluroMax-3 
spectrofluorometer.  This instrument is equipped with a four-cuvette rotating sample 
holder.  The cell holder was attached to an external water bath to control the temperature.  
The FluoroMax-3 was operated using the DataMax spectroscopy software provided by 
the manufacturer.  A protein concentration of approximately 1.0 μM was used in the 
experiments.  The emission intensity was recorded using an excitation wavelength of 280 
nm and an emission wavelength of 338 nm with a band pass of 3 nm for both excitation 
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and emission slits.  Wavelength calibrations for both the excitation and emission 
monochrometers were performed regularly using xenon lamp and water Raman scans as 
described by the manufacturer. 
2.5 
Kinetic assays for the effect of anions on iron removal from transferrin by the 
saturation and first order pathways   
2.5.1 
Ligands that follow saturation kinetics 
 The ligands acetohydroxamic acid and deferiprone follow saturation kinetics for 
iron release by transferrin (8).  Iron release from C-terminal monoferric transferrin by 
200 mM AHA was monitored for 4.5 hours.  Similarly, iron release from C-terminal 
monoferric transferrin by 20 mM deferiprone (L1) was monitored for 10 hours.  
2.5.2 
Ligands that follow first order kinetics 
 The ligands nitrilotriacetic acid and diethylenetriaminepentaacetic acid follow 
first order kinetics for iron release from transferrin (9;10).  Iron release from C-terminal 
monoferric transferrin by 100 mM NTA was monitored for 4.5 hours.  Similarly, iron 
release from C-terminal monoferric transferrin by 200 mM DTPA was monitored for 10 
hours. 
2.5.3 
Effect of simple anions  
 The anions methanesulfonate, methylenedisulfonate, ethylenedisulfonate, 
methylphosphonate, 3-phosphonopropionate, and phosphonoacetaamide are not effective 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.58 
 
58 
 
chelating agents, and were classified as simple anions to indicate that they were incapable 
of removing iron from C-terminal transferrin.  Iron release reactions with ligands that 
follow saturation (AHA and L1) and or first order pathway (NTA and DTPA) were 
monitored in the presence of increasing concentrations of these anions.  To better 
compare results with and without anions, reactions were run side-by-side in two cuvettes.  
It was presumed that any change in the overall rate of iron release in the presence of these 
non-chelating molecules was a reflection of their binding at the KISAB on transferrin in 
such a way as to alter the rate of iron release by the reference ligand (i.e. AHA, L1 or 
NTA). 
2.5.4  
Effects of iron chelating anions 
 Some anions like phosphonoacetate and methylenediphosphonate are known to 
function as iron chelating agents (11).  The effect of these iron chelating anions were 
monitored on the ligands that follow saturation or first order pathway for iron removal 
from transferrin.  For these systems, in order to account for any day to day fluctuations in 
rate constants, three reactions were run simultaneously: one with the reference ligand that 
follows saturation or first order pathway alone, one with the chelating anion alone and 
one with a mixture of the reference ligand and the chelating anion.   
 In the cuvette with the mixture of reference ligand and chelating anion, the overall 
rate of iron release would reflect the combined rates of the two chelating agents.  To 
partition this overall rate between the two compounds, it was assumed that the reference 
ligands had no allosteric effect on the chelating anions.  Whenever the rate of the mixture 
was different from the sum of the rates of the individual components, it was assumed that 
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the deviation was due to an allosteric effect of the chelating anion on the rate of iron 
release by the reference ligand. 
 
2.6 
Data analysis 
2.6.1 
Kinetic assays for iron removal from ferric transferrin. 
C-terminal monoferric transferrin was used to determine the rate constant for iron 
removal.  The ligand was always in large excess to provide pseudo first order kinetics 
with respect to iron removal.  The value of kobs is calculated for each ligand concentration 
from a least squares fit of fluorescence intensity or absorbance versus time. 
 At high concentrations of ligand, the iron removal reactions go to completion, and 
the kinetic data are fit to equation (2.1). 
 
 (2.1) 
 
where, I0, I∞ and It are the intensities at time zero, at infinite time and at any intermediate 
time t, and kobs is the first order rate constant.  Depending on the type of methods used the 
intensity (I) obtained from the fluorimeter can be replaced by absorbance (A) as 
measured using the UV-vis spectrophotometer.   
 The release of iron from transferrin is a reversible process.  At low ligand 
concentrations, the reaction does not go to completion.  Instead, it reaches equilibrium as 
shown in equation 2.2. 
( ) ∞−∞ +−= IeIII tkt obsο
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Fe-Tf + L Fe-L + Apo-Tf
kf
kr
 
                                                                                                                      (2.2) 
 
Even when the reactions do not go to completion, there is still a significant excess 
of ligand over transferrin, so this equilibrium is pseudo first order in the forward 
direction.  However, the products, FeL and apoTf, are produced in equimolar 
concentrations, so the reaction is second order in the reverse direction.  The treatment of 
such systems is described by Moore and Pearson (12).  For these systems, the final 
intensity (Ie), is the intensity at equilibrium.  The final intensity that would have been 
observed if the reaction had gone to completion (I∞) was obtained from a parallel reaction 
run using a ligand concentration high enough to force the iron removal reaction to go to 
completion.  For reactions going to equilibrium, the intensity change at any intermediate 
time (ΔIt) is It – I0 where I0 is the intensity at time zero.  The value of ΔIt as the function 
of time is given by the equation 2.3. 
 
                        
( )
tk
e
tk
e
t
f
f
eIII
eII
I α
α
00
0 1
Δ+Δ−Δ
−ΔΔ=Δ                                  (2.3) 
 
where, ΔI0 = I∞ - I0, ΔIe = Ie – I0,  
( )
( )e
e
I
II
Δ
Δ−Δ= 02α  and kf is the rate constant for iron 
release in equation (2.2).  Rate constants were calculated by using equation (2.1) or 
equation (2.3) and are referred to as kobs. 
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2.6.2 
Effect of simple anions on the saturation and first order pathways for iron release 
from transferrin 
The simple (i.e. non-chelating) anions used in this study are listed in section 2.5.1.  
Pseudo-first-order rate constants were measured for paired samples of the reference 
ligand, one with and one without the added anion  The change in the apparent rate of iron 
release by the reference ligand is expressed as shown in equation (2.4), 
'
% 100obs obs
obs
k kk x
k
−Δ =   
(2.4) 
where kobs is the rate constant for iron release by the reference ligand alone, and 'obsk  is 
the rate constant for the same concentration of the reference ligand in the presence of the 
added anion.  The reference ligands and their concentrations were AHA (200 mM), L1 
(20 mM), NTA (100 mM) and DTPA (200 mM).  
2.6.3 
Effect of chelating anions on the saturation and first order pathways for iron release 
from transferrin 
 Pseudo-first-order rate constants were measured simultaneously in three cuvettes, 
one for the reference ligand (L), one for the chelating anion (A) and one for the mixture 
of ligand and anionic ligand (L+A).  The apparent rate constant for iron release reflected 
the combination of iron release by the ligand (L) and the chelating anion (A) as shown in 
equation (2.5).   If there are no allosteric effects, the observed rate constant for the 
mixture should be the sum of the rate constants of the two components.  When the 
observed rate constant of the mixture is other than the simple sum of the rates for the two 
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components, it is assumed that the chelating anion has acted allosterically to alter the rate 
of iron release by the reference ligand.  This altered rate of iron release by the reference 
ligand is referred to as kapp, and is calculated as shown in equation (2.5) 
 
                          ݇௔௣௣ሺܮሻ ൌ  ݇௢௕௦ሺܮ ൅ ܣሻ െ ݇௢௕௦ሺܣሻ                                   (2.5) 
 
The effect of the chelating anion on the reference ligand was expressed as shown 
in equation (2.6) 
 
                       %∆݇௢௕௦ ൌ
௞ೌ೛೛ሺ௅ሻି௞೚್ೞሺ௅ሻ 
௞೚್ೞ ሺ௅ሻ
ൈ 100                              (2.6) 
 
The program SigmaPlot from SYSTAT was used extensively to analyze the data.  The 
analyses involved some library functions from Sigmaplot as well as some user-defined 
functions coded and stored in the program.  SigmaPlot was also used to prepare all the 
graphs contained in this dissertation. 
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Chapter 3 
 
Kinetics of Iron Removal from C-terminal Monoferric Human Serum Transferrin 
by Bifunctional Ligands 
3.1 
Introduction 
The concept of bifunctional ligands arises from previous studies involving 
mediated iron release (1;2), in which a smaller, weaker ligand mediates the transfer of 
iron from transferrin to a larger, more powerful iron sequestering agent.  Ligands like 
desferrioxamine B (DFO) have a strong iron binding affinity (3), but the rate of iron 
release from transferrin is very slow (4).  In the course of studies involving the synthesis 
of potential orally active ligands that can replace DFO, a class of iron(III)-selective 
chelators, the hydroxypyridinones, have been studied (5;6).  These are six membered 
rings with adjacent keto and hydroxyl functional groups.  3-Hydroxy-4-pyridinones 
(Figure 3.1a) and 3-hydroxy-2-pyridinones (Figure 3.1b) have both been used to remove 
iron from iron overloaded animals (7-10).  The 3-hydroxy-4-pyridinones have been more 
extensively investigated in humans (11-13). 
 
                                                              
N O
OH
R    
      a) 3-hydroxy-4-pyridinones                                b) 3-hydroxy-2-pyridinones 
Figure 3.1   Structures of hydroxypyridinones   
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Compared with the hydroxypyridinones, ligands like phosphonoacetic acid (PAA) 
are weaker binding agents, but they can remove iron from transferrin more rapidly.  Any 
potential candidate for iron chelation therapy must have a higher binding affinity than 
simple ligands like PAA.  The presence of the central methylene group in PAA makes it 
possible to add a new functionality to this ligand.  Also, previous studies on 
monosubstituted PAA derivatives indicate that a metal-binding functional group can be 
added to PAA (14;15).  Thus a potential bifunctional ligand that is expected to increase 
the metal-binding affinity without drastically decreasing the rate of iron release can be 
synthesized.  We are interested in evaluating iron release kinetics by bifunctional ligands.  
These ligands contain one functional group that accelerates iron release and a second 
functional group that increases the iron-binding affinity. 
 One such bifunctional ligand, 3,2-hopoPAA was synthesized for our studies by 
Dr. C. Spilling’s group at UMSL.  The structure for 3,2-hopoPAA is shown in Figure 3.2 
and has a phosphonoacetic acid at one end conjugated to 3-hydroxy-2-pyridinone by four 
methylene groups. 
 
 
 
 
 
 
Figure 3.2   Structure of 3-hydroxy-2-pyridinone-PAA 
N
P
O
OH
OH
HO
O
O
OH
3,2-hopo-PAA
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The rationale is that PAA would facilitate the rapid release of iron.  The four -CH2 groups 
can fold to bring the PAA and 3-hydroxy-2-pyridinone together to act as a tetradentate 
ligand, so 3,2-hopo-PAA is expected to bind iron much more strongly than PAA alone.   
 The main focus of this research project is to measure the rate of iron release by 
3,2-hopo-PAA and compare this to the rates obtained by PAA and 3-hydroxy-2-
pyridinone individually.  We measured the rates of iron release at low ligand 
concentrations of phosphonoacetic acid (PAA) and its methyl and ethyl derivatives to 
study the impact of alkyl substituents on iron release by PAA and on the concentration of 
ligand required to reach saturation.  This was important in relation to clinically useful 
drug concentrations.  We attempted to measure the rates of iron release from 2,3-
dihyroxy pyridine (2,3 DHP) and  N-methyl-3-hyroxypyridin-2-one (3HMPY) to get an 
estimation for the  rates before we switched to 3,2-hopo-PAA.  The experiments with 2,3 
DHP and 3HMPY were difficult to carry out due to the problem of slow air oxidation of 
the ligand.  These kinetics studies using 2,3 DHP and 3HMPY are reported in this 
chapter. 
 
3.2 
Results 
Iron release kinetics from C-terminal monoferric transferrin at low concentrations 
of phosphonocarboxylates 
Phosphonocarboxylates appear to be able to substitute for the synergistic 
carbonate anion (15) and show a significant rate of iron removal from transferrin.  Iron 
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removal kinetics by phosphonoacetic acid (PAA) have been studied previously by using 
Uv-vis spectroscopy (2;15).  Iron release from N-terminal monoferric transferrin by PAA 
shows a linear dependence of the rate constant kobs on the ligand concentration over the 
concentration range of 20-200 mM PAA.  The linearity of the plot and the nonzero 
intercept are consistent with equation (3.1) for complex kinetics, assuming that [L] >> kd 
over the available range of ligand concentrations.  Under these conditions, equation (3.1)  
 
                           max[ ] '[ ]
[ ]obs d
k Lk k L
k L
= ++                                           (3.1) 
 
reduces to equation (3.2), a simple linear equation with slope of k’ and a y-intercept of 
kmax. 
 
                                         ]['max Lkkkobs +=                                                (3.2) 
 
Under these conditions kd, which is the concentration of ligand required to reach 
half saturation, could not be determined.  It was assumed that the plot of kobs versus PAA 
concentration would curve towards zero at low ligand concentrations (2;15).  For any 
ligand to be a potential drug, it is important to study its behavior at low concentrations.  
Hence, we are interested in studying iron release at low concentrations of PAA to define 
the kd value. 
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3.2.1 
Kinetic studies of iron removal from C-terminal monoferric transferrin by PAA, 
methyl-PAA and ethyl-PAA. 
Iron release kinetics from C-terminal monoferric transferrin by PAA were 
monitored by using fluorescence spectroscopy, where we could follow kinetics at low 
concentrations of PAA.  As expected, the plots curve towards zero at low concentrations 
of PAA, as shown in Figure 3.4.  The data in Figure 3.4 were fitted to equation (3.1) for 
complex kinetics, and the rate parameters obtained are listed in Table 3.1.  The presence 
of the central methyl group in PAA provides a position for substitution, and various PAA 
derivatives are available commercially.  Kinetics of iron removal from N-terminal 
monoferric transferrin by methyl and ethyl derivatives of PAA have been studied by our 
group previously using Uv-vis spectroscopy (2;15).  The methyl and ethyl groups are 
noncoordinating substituents and can be used for elongation of the ligand. 
 
   
                         
 
Figure 3.3.  Structures of phosphonoacetic acid, methyl-PAA and ethyl-PAA 
 
We monitored iron release from C-terminal monoferric transferrin using methyl- 
and ethyl-PAA at low concentrations using fluorescence spectroscopy.  The observed 
rates were plotted against the concentrations of the ligands in Figure 3.4.  The rates for 
iron release decrease in the order PAA > methyl-PAA > ethyl-PAA.  It was previously 
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reported that elongation of the ligands slows the rate of iron release from N-terminal 
monoferric transferrin (2), and the same trend on elongation of PAA is observed for iron 
release from C-terminal monoferric transferrin.  The methyl-PAA and ethyl-PAA also 
follow the combination of saturation and first order pathway as observed for PAA.  The 
rate parameters for these ligands are listed in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Rate constant for iron release from C-terminal monoferric transferrin 
by phosphonoacetic acid (PAA), methyl phosphonoacetic acid (MPAA) and ethyl 
phosphonoacetic acid (EPAA) in 0.1 M Hepes at pH 7.4 and 25 °C 
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Table 3.1 
Rate parameters for iron release from C-terminal monoferric transferrin  
 kmax (min-1) x 103 kd  (mM) k' (M-1 min-1) 
PAA 17 ± 4 10  ± 5 0.38  ± 0.02 
MPAA 26 ± 9 25  ± 14 0.28 ± 0.04 
EPAA 40 ± 18 82 ± 37 0.20 ± 0.05 
 
In this study we report the rate parameters for C-terminal monoferric transferrin 
with respect to the methyl and ethyl derivatives of PAA for the first time, as the earlier 
studies were focused on N-terminal transferrin.  Also, we report the kd values for PAA 
for the C-terminal monoferric transferrin, which could not be determined by using uv-vis 
spectroscopy. 
 
3.2.2 
Iron removal from C-terminal monoferric transferrin by 2, 3-dihydroxypyridine 
(2,3 DHP).  
After completing the iron removal studies by PAA and its derivatives, we selected 
2,3-dihyroxypyridine (2,3 DHP)  for the second phase of our kinetic studies as it was 
commercially available.  Before we get on to the results that we obtained, we would 
discuss some of the issues that we faced during the course of our research.  The 
commercial sample of 2,3 DHP is a brown colored solid and gives a light brown colored 
solution in 0.1 M Hepes at pH 7.4.  We treated the ligand solution with activated 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.71 
 
71 
 
charcoal, but did not observe any drastic change in the color of the solution.  The 
solutions of 2,3 DHP also appeared to be unstable, presumably due to slow air oxidation.  
Over time, the light brown colored solution would change to dark brown, making it even 
more difficult to obtain accurate visible spectra of the iron-DHP complex and of mixtures 
of ferric-transferrin and DHP.  We prepared 2,3 DHP solutions by bubbling with argon 
for 5-10 min, filtering the oxygen-free solutions, and adjusting the pH to 7.4.  Thus 
freshly prepared solutions of the ligand were clear and yellowish brown in color.  The 
visible spectrum for the Fe(2,3-DHP)3 complex was obtained by using the 2,3 DHP 
solution as a reference.  As shown in Figure 3.5, the iron complex has two peaks at 410 
nm and 500 nm, which represent ligand-to-metal charge transfer bands. 
 
Figure 3.5.  The visible spectrum of the Fe(2,3 DHP)3 complex in 0.1 M Hepes pH 
7.4 at 25 °C. The trace in green is the iron complex and the trace in red is for the 
blank (2,3 DHP). 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.72 
 
72 
 
 
After determining the wavelengths at which the Fe tris 2,3 DHP complex is 
formed, we began kinetic studies with C-terminal monoferric transferrin and 2,3 DHP.  
The ligand was added to samples of C-terminal monoferric transferrin, and spectra from 
350-600 nm were recorded.  Representative scans for the reaction of 30 μM CTf and 50 
mM 2,3 DHP  over the course of 4 to 5 hours are shown in Figures 3.6 and 3.7. 
 
 
Figure 3.6.  Spectra collected during the reaction of monoferric transferrin with 50 
mM 2,3- dihydroxypyridine (2,3 DHP) for 4 hours at 25 °C in 0.1 M Hepes.  The 
isosbestic point at 370 nm was maintained during the course of the reaction. 
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Figure 3.7.  Spectra collected during the reaction of monoferric transferrin with 50 
mM 2,3-dihyroxy pyridine (2,3 DHP) for 5 hours at 25 °C in 0.1 M Hepes. The 
isosbestic point at 370 nm was maintained till 50 min. 
 
Figures 3.6 and 3.7 show the spectra obtained for the same reaction on two 
different days.  In Figure 3.6, the isosbestic point was maintained throughout the reaction, 
whereas in Figure 3.7, we observed an isosbestic point around 370 nm that was 
maintained for about an hour, but was lost with the progression of time.  The loss of the 
isosbestic point was indicative of some form of ligand oxidation.  Due to this sort of 
variability observed for the same and different ligand concentrations, it was difficult to 
reproduce our data.  For our studies to continue, we needed stable ligand solutions. 
We also attempted to prepare the hydrochloride salt of 2,3 DHP in an effort to 
obtain a colorless sample of the ligand.  We tried several experiments under different 
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conditions but could never obtain a colorless salt of 2,3 DHP.  Simultaneously, we 
searched for commercial sources of derivatives of 2,3 DHP that might be more air-stable 
and obtained 5-chloro-2,3-dihyroxypyridine from Alfa Aesar.  This ligand was also light 
brown to buff in color and had a very low solubility in 0.1 M Hepes buffer.  The issue 
with colored ligand solutions was not resolved. 
 
3.2.3 
Iron removal from C-terminal monoferric transferrin by N-methyl-3-
hydroxypyridin-2-one (3HMPY) 
 We decided to switch to the ligand N-methyl-3-hyroxypyridin-2-one (3HMPY).  
This ligand was off white in color and was soluble in 0.1 M Hepes at pH 7.4.  To 
determine the spectrum of the Fe(3HMPY)3 complex, we added 0 to 1 equivalents of 
Fe(III) to 3HMPY solutions.  We observed two peaks, a smaller peak at 410 nm and at 
larger peak at 500 nm.  During experiments on the removal of iron from transferrin, we 
monitored the kinetics at these two wavelengths because they present the maximum 
change in the absorbance.  Rate constants were calculated using data from each 
wavelength. 
We carried out kinetic studies on the removal of iron from C-terminal monoferric 
transferrin by 150, 125, 100 and 50 mM concentrations of 3HMPY.  The experiments 
were difficult to carry out at 50 mM 3HMPY concentrations.  The ligand solutions were 
very unstable, and it was difficult to distinguish between the degassed and not degassed 
samples.  For the higher concentrations of 3HMPY, we performed scanning kinetics over 
the range of 350-600 nm and obtained an isosbestic point around 370 nm.  Representative 
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scans for iron removal by 100 mM 3HMPY and 125 mM 3HMPY are shown in the 
Figure 3.8 and Figure 3.9, respectively. 
 
 
Figure 3.8.  Spectra collected during the reaction of monoferric transferrin with 100 
mM 3HMPY for 5 hours at 25 °C in 0.1 M Hepes.  There is an isosbestic point at 370 
nm, which was maintained during the course of the reaction. 
 
The isosbestic point for the reaction of monoferric transferrin and 100 mM 
3HMPY as shown in Figure 3.8 was maintained for the entire duration of the reaction.  
However, the stability of the isosbestic point was inconsistent.  For example, when the 
reaction of monoferric transferrin with 125 mM 3HMPY was monitored, the isosbestic 
point was lost after about 4 hours, and a new peak at 375 nm appeared, as shown in 
Figure 3.9.  The loss of the isosbestic point indicates the formation of some other species.  
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The absorbance changes measured up to the loss of the isosbestic point were fit to 
equation (2.1) from Chapter 2, and the resulting rate constants are listed in Table 3.2. 
 
 
Figure 3.9.  Spectra collected during the reaction of monoferric transferrin with 125 
mM 3HMPY for 9 hours at 25 °C in 0.1 M Hepes. The isosbestic point is lost after 
about 4 hours and the emergence of a new peak at 375 nm was observed. 
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Table 3.2 
The observed rates for iron removal from 30 μM C-terminal monoferric transferrin by 
3HMPY in 0.1 M Hepes, pH 7.4 at 25 °C. 
3HMPY (mM) kobs (min-1) 
 410 nma 500 nma 
100 0.0077 0.0087 
125 0.0080 0.0089 
150 0.0110 0.0119 
 aWavelength at which absorbance changes were monitored. 
 
The observed rates for the higher concentration of 3HMPY indicate that the rate of iron 
release is close to reaching saturation with respect to the ligand concentration.  The rates 
also indicate that the removal of iron by 3HMPY is very slow.  These rates are 
comparable to the rate of L1 at 100 mM (0.007 min-1) (16).  
 
3.3 
Discussion  
 Rate constants for iron release from C-terminal monoferric transferrin over a wide 
ligand concentration range were measured for PAA and its methyl- and ethyl- 
derivatives.  The plots in Figure 3.4 show that the short alkyl substituents cause a modest 
decrease in the overall rate of iron release.  This suggests that steric factors are unlikely 
to drastically reduce the rate of iron release by bifunctional PAA ligands such as 3,2-
hopo-PAA. 
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The data in Figure 3.4 were then used to determine the rate parameters listed in 
Table 3.1.  The rate parameters indicate that the overall rates of iron release remain 
relatively constant due to offsetting effects on the parameters for the saturation and first-
order components.  Alkyl substituents increase the kmax value for the saturation 
component, but reduce the rate constant k' of the first-order component.   
A higher kmax should be an advantage for in vivo iron chelation since the ligand 
concentrations in vivo must be low.  Unfortunately, this potential advantage is negated by 
the increase in kd values for the alkyl substituents, which reduces the degree of saturation 
at low ligand concentrations.  One can speculate that the alkyl substituents increase kd by 
weakening the binding of the ligand in the mixed-ligand intermediate of the Bates 
mechanism (17).  The kmax value represents the forward rate constant of the protein 
conformational change.  In the simple Bates mechanism, this value should be 
independent of the ligand.  The variations in kmax shown in Table 3.1 are likely to be due 
to the binding of the ligands to an allosteric anion binding site.  This type of allosteric 
effect is discussed in detail in Chapters 4 and 5. 
The second part of this study on iron removal by 2,3 DHP and 3HMPY obviously 
has serious limitations.  Both ligands give a high background absorbance spectrum, but 
the much more serious problem is that the ligand spectrum changes over the long time 
frames needed to measure the relatively slow iron release from transferrin by these 
ligands.  We were unable to develop an experimental procedure that could avoid or 
compensate for these slow changes in the ligand spectrum, and thus we did not attempt a 
detailed kinetics analysis.   
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In spite of the experimental problems, the rate constants in Table 3.2 provide 
useful information on iron release by 3,2-hopo ligands.  There is only a small increase in 
the rate constant over the concentration range of 100-150 mM ligand, which indicates 
that the reaction follows saturation kinetics, and is running close to saturation over this 
concentration range.  Since saturation requires a ligand concentration of about 5 x kd, we 
can make a rough estimate of kd of around 25 mM.  This appears to be slightly higher 
than the kd values of 0.8 mM for L1 and 6 mM for 1-hydroxypyridin-2-one (16). 
Nevertheless, the kd for 3HMPY is clearly much lower than the value of 180 mM 
previously reported for acetohydroxamic acid (16).  
The rate constants for HMPY listed in Table 3.2 are rather low, ~0.01 min-1.  One 
would certainly prefer higher rate constants, but these values are quite similar to the kmax 
value of 0.007 min-1 reported for L1 (16).  Since L1 has shown reasonable biological 
activity (5;7), one would conclude that the rates of iron removal by 3HMPY are large 
enough to make this group viable as an in-vivo chelator. 
In summary, the observations that 3HMPY has a rate of iron release comparable 
to L1 and that substitution at the methylene group of PAA does not significantly reduce 
the rates of iron release by PAA derivatives are both favorable indicators that the 
proposed bifunctional ligand shown in Figure 3.2.  Unfortunately, experimental problems 
associated with changes in the ligand spectrum, possibly due to slow ligand oxidation, 
have thus far prevented any assessment of the rates of iron release by 3,2-hopo-PAA.  
There is a very limited supply of this compound, and we are unwilling to use it until we 
are confident that we have an effective experimental protocol. 
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Chapter 4 
Effect of Sulfonate Anions on the Kinetic Pathways for Iron Removal from 
Transferrin 
 
4.1 
Introduction 
 This chapter is an attempt to have a better understanding of the effects of 
allosteric anions on the saturation and first order pathways of iron release.  We have 
focused on a series of sulfonates with one or two anionic functional groups to study their 
effect on the first order and saturation pathways of iron release.  The results obtained are 
presented in this Chapter. 
 
4.1.1 
Kinetic Pathways for Iron removal from Transferrin 
 The dependence of the rate of iron release on the ligand concentration shows a 
complex variation among different chelating agents.  Iron removal by many ligands, such 
as acetohydroxamic acid (AHA) and deferiprone (1;2), follows simple saturation kinetics 
with respect to the ligand concentration, as described by equation (4.1). 
 
                                             max
[ ]
[ ]obs d
k L
k
k L
= +                                                            (4.1) 
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This kinetic behavior is usually explained by the Bates mechanism (1), which is shown 
below as originally proposed for iron release by the bidentate chelating agent 
acetohydroxamic acid (AHA). 
                                                            k1 
   Fe-CO3-Tf                  Fe-CO3-Tf*                              (4.2) 
     k-1 
 
      k2 
           Fe-CO3-Tf*   +    AHA            AHA-Fe-CO3-Tf*                      (4.3) 
                      k-2 
 
                k3 
 AHA-Fe-CO3-Tf* + 2 AHA            Fe(AHA)3  + apoTf + CO32-               (4.4) 
 
 
 The first step in the mechanism is a conformational change from the normal 
“closed” form of the holoprotein into an “open” conformation designated by the asterisk.  
In the second step, the incoming ligand attacks the now exposed ferric ion, which is 
removed from the protein in the third step.  The intermediate complex was detected 
spectroscopically during the donation of iron from Fe(AHA)3 to apoTf, but was not 
detected during iron release.  This led to the hypothesis that it is the slow conformational 
change in equation (4.3) that is rate limiting for iron release in the presence of high 
concentrations of the ligand.  Based on this mechanism, the kmax parameter in equation 
(4.1) corresponds to k1 in equation (4.2), the forward rate constant for the conformational 
change between the “closed” and “open” forms of the protein. 
 Many more recent studies have shown that not all systems conform to the Bates 
mechanism.  Several ligands, particularly pyrophosphate (3-7) and phosphonic acids 
(3;6;8) appear to follow saturation kinetics at low concentrations, but at higher ligand 
concentrations, the rate of iron release does not level off.  Instead, it continues to increase 
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linearly with the ligand concentration. The kinetic data for this class of ligands has been 
described by equation (4.5). 
 
                            max
[ ] '[ ]
[ ]obs d
k Lk k L
k L
= ++                                             (4.5) 
 
There have been various hypotheses to explain the first-order term in equation (4.5) 
(4;7;9;10).  This laboratory has proposed that k’ is the rate constant for a reaction 
pathway that involves the removal of iron from the closed conformation of the 
holoprotein (6;8;11).  
Perhaps the most intriguing variation in the pattern of ligand-dependence for iron 
removal from transferrin is shown by two simple aminocarboxylic acids, nitrilotriacetic 
acid (NTA) (11) and diethylenetriaminepentaacetic acid (DTPA) (8).  Iron release by 
both these ligands follows simple first order kinetics with respect to the ligand 
concentration.  It has been proposed that for these ligands, kmax is very small, such that 
equation (4.5) reduces to simple first-order dependence.  However, if kmax is associated 
with a protein conformational change, there is no obvious explanation for why these 
ligands are apparently unable to remove iron more rapidly from the open conformation. 
Iron release by any particular ligand is also affected by the presence of non-
synergistic anions.  This is not simply due to changes in ionic strength, nor can these 
anion effects be correlated with the lyotropic series.  The strongest effect is typically seen 
with perchlorate, which accelerates iron release from the C-terminal site, but significantly 
retards iron release from the N-terminal site (12).  Because the anion effects are so 
selective and variable, Egan and co-workers have proposed that there is an allosteric 
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anion binding site in each lobe, referred to as the kinetically significant anion binding 
(KISAB) site (13).  Within the context of the Bates conformational change mechanism, 
one might expect that anion-binding at the KISAB site alters the rate of the 
conformational change between open and closed forms of the protein.  However, neither 
the location and nor the structure of the purported allosteric anion binding site has been 
identified, and these anion effects on iron release rates are poorly understood (14-16). 
We have initiated a study to obtain a better understanding of the effects of 
allosteric anions on the saturation and first order pathways for iron release.  A series of 
sulfonates with one or two anionic functional groups were evaluated for their ability to 
alter the rate of iron removal from transferrin by acetohydroxamic acid (AHA), 1,2-
dimethyl-3-hydroxy-4-pyridinone (deferiprone), nitrilotriacetic acid (NTA), and 
diethylenetriaminepentaacetic acid (DTPA).  These ligands were chosen because AHA 
and deferiprone remove iron via simple saturation kinetics (1;2), while NTA and DTPA 
remove iron via simple first-order kinetics (8;11).  Sulfonic acids were chosen because 
they are strictly non-chelating molecules that cannot remove any iron from transferrin, 
and thus introduce no complications in the analysis of the kinetic data.  Iron removal 
from C-terminal monoferric transferrin has been studied to avoid the complications of 
analyzing simultaneous iron release from both of the binding sites in diferric transferrin. 
 
4.2 
Results 
4.2.1 
Effect of simple anions on iron release by AHA 
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The rates of iron release from transferrin by 200 mM AHA in the presence of a 
series of anions have been measured.  These include the simple inorganic anions chloride 
and perchlorate, as well as the organic anions methylphosphonate (MPA), 
methylsulfonate (SMS), and acetate.  The results are shown in Table 4.1.  The 
acceleration of iron release by chloride and perchlorate agrees with several previous 
studies (2;12;17;18).  The organic anions used in this study also accelerate iron release, 
but to a lesser degree compared with chloride and perchlorate.  
 
Table 4.1 
 Effect of simple anions on the rate of iron removal by 200 mM AHAa 
          kobs (min-1) x 103 
200 mM [AHA] 16.2 + 0.4 
[AHA] + 100 mM  Cl - 31.8 + 1.5 
[AHA] + 100 mM ClO4- 69.0 + 0.4 
[AHA] + 100 mM  MPA 25.4 + 0.2 
[AHA] + 100 mM  SMS 22.9 + 0.2 
[AHA] + 100 mM  Acetate 20.4 + 0.3 
a0.1 M HEPES, pH 7.4, 25 ºC 
 
4.2.2 
 Effect of sulfonates on iron removal by the saturation pathway 
Rates of iron release by AHA were measured in the presence of increasing 
concentrations of methanesulfonate (SMS), methanedisulfonate (MDS) and 
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ethanedisulfonate (EDS).  Sulfonic acids are extremely weak coordinating groups, and 
separate experiments verified that these anions do not remove any significant amount of 
iron from transferrin over the concentration range used in this study.  Thus any change in 
the observed rate constant for iron release in the presence of the sulfonate has been 
attributed to the allosteric effect of the anions binding to the KISAB site on the protein 
and altering the rate constant for iron removal by AHA. 
Iron removal from C-terminal monoferric transferrin by 200 mM AHA went to 
completion in all the sulfonate samples, and values of kobs were calculated as described in 
Chapter 2 by use of equation 2.1.  To minimize the effect of any day-to-day variations in 
the rate constants on the assessment of the anion effects, pseudo-first-order rate constants 
were measured for paired samples, one with and one without, the added sulfonate anion.    
In the absence of added anion, the average rate constant for iron release by 200 
mM AHA is 0.016 min-1.  All three sulfonate anions increased this rate constant.  This 
acceleration is expressed as shown in equation (4.6), 
 
                                    
'
% 100obs obs
obs
k kk x
k
−Δ =                                        (4.6) 
 
where kobs is the rate constant for iron release by 200 mM AHA alone, and 'obsk  is the rate 
constant for the same concentration of AHA in the presence of the added anion.  Values 
of %Δk as a function of the anion concentration for the series of sulfonate anions are 
shown in Figure 4.1. 
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Figure 4.1.  Plots of %Δk (equation 4.6) for the removal of iron from C-terminal 
monoferric transferrin by 200 mM AHA in the presence of sodium methane 
sulfonate (SMS), methanedisulfonate (MDS), and ethanedisulfonate (EDS) at 25 oC 
in 0.1 M Hepes, pH 7.4.  The concentration shown for SMS is the actual molarity 
divided by two to give the equivalent concentration of a disulfonic acid. 
 
 A similar set of kinetic experiments with sulfonates were conducted using 20 mM 
deferiprone to remove the iron.  Iron release went to completion in all cases, and rate 
constants with (kobs’) and without (kobs) anions were calculated as described in Chapter 2 
by using the version of equation (2.1) with absorbance rather than fluorescence intensity.  
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The average rate constant for iron release in the absence of anions was 0.005 min-1.  The 
effect of sulfonates on the rate of iron release by deferiprone is shown in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Plots of  %Δk (equation 4.6) for the removal of iron from the C- terminal 
monoferric transferrin by 20 mM deferiprone in the presence of sodium 
methanesulfonate (SMS), methanedisulfonate (MDS), and ethanedisulfonate (EDS) 
at 25 °C in 0.1 M Hepes, pH 7.4. The concentration shown for SMS is the actual 
molarity divided by two to give the equivalent concentration of a disulfonic acid.  
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As seen in Figures 4.1 and 4.2, the %Δk values for these two neutral ligands show 
a linear dependence on the concentration of the sulfonates.  For both ligands, disulfonates 
have a significantly greater impact than SMS.  For the two disulfonates, the length of the 
alkyl linker between the two anionic functional groups has an effect on the kinetics.  
Faster rates are observed with MDS, in which the sulfonates are separated by a single 
methylene group. 
Iron release by 200 mM AHA was also measured in the presence of 100 mM 
perchlorate.  This concentration of perchlorate increased the rate constant from 0.0162 
min-1 to 0.069 min-1, which corresponds to a %∆k of 330.  Thus for iron release by AHA, 
it appears that the effect of MDS is essentially the same as the effect of perchlorate. 
It is possible that each of the sulfonic acid groups of the disulfonate anions 
interacts independently with the protein, and that the greater effect on iron release 
compared with SMS just reflects the fact that the effective molarity of sulfonic acid 
groups is doubled for MDS and EDS.  We have corrected for this mismatch in 
stoichiometry by plotting the SMS data using the actual molarity of SMS divided by two.  
Thus when one compares the kinetic effects at any given concentration in Figures 4.1 and 
4.2, each of the three solutions contains the same total concentration of sulfonate groups.  
Even with this correction, it is quite clear that the disulfonates have a greater impact on 
iron release kinetics.  In addition, MDS produces a larger effect than does EDS.  Thus our 
hypothesis is (a) these anions are binding to a specific allosteric site on the protein, (b) 
this binding involves both sulfonated groups of the anion, and (c) the structure of the 
allosteric site results in a preference for the shorter MDS dianion. 
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 Previous studies on iron removal by AHA and deferiprone have shown that the 
ligand dependence of kobs reflects simple saturation kinetics as described by equation 
(4.1) (1;2).  The presence of a sulfonate in the solution could accelerate the observed rate 
of iron release at a given concentration of AHA by increasing the value of kmax, by 
decreasing the value of kd, or by producing a first-order term for iron release as shown in 
equation (4.5).  To differentiate among these possibilities, values of kobs were measured 
for iron removal by varying concentrations of AHA in the presence of a constant 
concentration of 50 mM MDS.  The results are shown in Figure 4.3.  Below 75 mM 
AHA, the iron removal reaction no longer goes to completion, and the value of kobs was 
calculated as described in Chapter 2 using equation (2.3) to fit the intensity versus time 
data. 
 The ligand-dependence of kobs in the absence and in the presence of 50 mM MDS 
has been modeled using both equation (4.1) (simple saturation kinetics using two 
adjustable parameters) and equation (4.5) (saturation-linear kinetics using three 
adjustable parameters).  The results from the least squares fits are listed in Table 4.2.  For 
iron release when MDS is present, the functions in equations (4.1) and (4.5) give 
essentially identical fits to the experimental data.  This can be seen visually from the 
overlap of the plots of these two functions.  The addition of the third adjustable parameter 
in equation (4.5) produces a statistically insignificant improvement in the sum of squares 
of the residuals from the fit, as assessed by an R-factor ratio test (2).  In addition, the 
value of k’ calculated by use of equation (4.5) has an error of almost 100%. 
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Figure 4.3.  Plots of kobs for the removal of iron from C-terminal monoferric 
transferrin by varying concentrations of AHA alone and in the presence of 50 mM 
MDS at 25 oC, in 0.1 M Hepes, pH 7.4. 
 
 Figure 4.3 also shows that there is a very strong overlap in the fits of the data in 
the absence of MDS to equation (4.1) and (4.5).  Iron release by AHA has been 
previously reported to follow simple saturation kinetics (1;2).  Thus it was surprising that 
the addition of the third adjustable parameter resulted in a small, but statistically 
significant, improvement in the fit obtained using equation (4.5).  The reason for this is 
not clear.  Given the previous literature reports of simple saturation kinetics and the 
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strong similarity in the fits to equation (4.1) and (4.5), we feel it is most appropriate to 
accept the fit to simple saturation kinetics as described by equation (4.1).  Thus we 
conclude that iron release by AHA follows simple saturation kinetics as described by 
equation (4.1) both alone and in the presence of MDS. 
Based on a comparison of the fits to equation (4.1), the results in Table 4.2 show 
that the presence of 50 mM MDS produces a four-fold increase in the kmax for iron 
release by AHA from 0.018 min-1 to 0.072 min-1.  The MDS also causes an increase in kd 
from 81.8 mM to 145 mM.  Because of this change in kd, a given concentration of AHA 
corresponds to different degrees of saturation with and without MDS.  The plot in Figure 
4.3 for iron release in the absence of MDS extends to 400 mM AHA, which corresponds 
to 83% of saturation.  The data for iron release in the presence of MDS extend to 300 
mM, but due to the larger value of kd, this represents only 67% of saturation.  Thus the 
increase in the rate of iron release in the presence of MDS that is shown in Figure 4.3 is 
due entirely to a large increase in the kmax for iron release. 
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Table 4.2 
Rate constants for iron removal from C-terminal monoferric transferrin by AHAa 
 kmax (min-1) x 103 kd  (mM) k’ (M-1 min-1) σy 
AHA aloneb 18.4 + 0.4 81.8 + 5.8 -- 0.00052 
AHA alonec 12.1 + 0.1 42.2 + 4.7 0.012 + 0.002 0.00031 
AHA + 50 mM 
MDSb 
71.6 + 0.4 145 ± 18 -- 0.0017 
AHA + 50 mM 
MDSc 
50 + 20 97 + 47 0.037 + 0.036 0.0017 
 
a 25 oC, 0.1 M Hepes, pH 7.4 
bData fit using two adjustable parameters to equation (4.1) 
cData fit using three adjustable parameters to equation (4.5)  
 
4.2.3  
Effect of sulfonates on iron removal by the first order pathway 
 The rates of iron release from transferrin are first-order with respect to the ligand 
concentration for both NTA and DTPA.  Rates of iron release by NTA and DTPA were 
measured in the presence of increasing concentrations of methanesulfonate (SMS), 
methanedisulfonate (MDS) and ethanedisulfonate (EDS).  Iron removal from C-terminal 
monoferric transferrin by 100 mM NTA goes to completion, and rate constants with 
(kobs’) and without (kobs) anions were calculated from data on paired samples using 
equation (4.6).  The acceleration in the presence of sulfonates is expressed as an increase 
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in %Δk as defined in equation (4.9).  The results for the effect of sulfonates on iron 
release by 100 mM NTA are shown in Figure 4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Plots of %Δk (equation 4.6) for the removal of iron from C- terminal 
monoferric transferrin by 100 mM nitrilotriacetic acid (NTA) in the presence of 
sodium methanesulfonate (SMS), methanedisulfonate (MDS), and  
ethanedisulfonate (EDS) at 25 oC in 0.1 M Hepes, pH 7.4.  The concentrations shown 
for SMS are the actual molarities divided by two to give the equivalent 
concentrations of a disulfonic acid. 
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 The effect of sulfonates on iron removal by 200 mM DTPA was also studied, and 
the results are shown in Figure 4.5.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  Plots of %Δk (equation 6) for the removal of iron from C- terminal 
monoferric transferrin by 200 mM diethylenetriaminepentaacetic acid (DTPA) in 
the presence of sodium methanesulfonate (SMS), methanedisulfonate (MDS), and  
ethanedisulfonate (EDS) at 25 oC in 0.1 M Hepes, pH 7.4.  The concentrations shown 
for SMS are the actual molarities divided by two to give the equivalent 
concentrations of a disulfonic acid. 
 
The effect of sulfonates on iron release by NTA and DTPA follows the same 
pattern as described above for AHA and deferiprone.  There is a smaller effect for the 
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monosulfonate, and a larger effect for both the disulfonates.  There is no significant 
difference in the effects of the two disulfonates.  However, the magnitude of the effect on 
iron release by NTA and DTPA is quantitatively smaller.  The rates of iron release by 
AHA and deferiprone were increased by ~400% by MDS, as compared to an increase of 
about 60% for iron release by NTA and DTPA. 
Values of kobs were also measured for iron removal by varying concentrations of 
NTA both in the absence and in the presence of a constant concentration of 75 mM MDS.  
The results are shown in Figure 4.6.  At concentrations of NTA below 75 mM, the iron 
removal reaction does not go to completion, and the value of kobs was calculated as 
explained in methods in Chapter 2 using equation (2.3) to fit the intensity vs time data.  
The data in the absence of MDS confirm previous reports (11) that iron release by this 
ligand is a simple first-order process, with an observed rate constant of 0.32 + 0.01 min-1.  
This rate constant is essentially identical to the value of k’ = 0.33 + 0.01 min-1 published 
previously (11).  The results in Figure 4.6 also confirm the previous report that the plot of 
kobs vs [NTA] has a zero y-intercept and thus shows no indication of a saturation 
component for iron release by this ligand. 
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Figure 4.6.  Plots of kobs for the removal of iron from the C-terminal monoferric 
transferrin by varying concentrations of NTA in the presence of a constant 75 mM 
MDS at 25 oC, 0.1 M Hepes, pH 7.4. 
 
It is obvious from the plot in Figure 4.6 that the addition of MDS has dramatically 
changed the ligand dependence of iron removal by NTA.  The reaction is clearly no 
longer a simple first-order process.  The data on iron removal in the presence of the MDS 
have been fit to both equation (4.1) and equation (4.5), and the resulting parameters are 
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shown in Table 4.3.  Visually the quality of the fits looks similar, but the use of equation 
(4.5) reduces the sum of squares of the residuals by 40% compared to that obtained by 
use of equation (4.1).  The improvement in the fit to equation (4.5) is statistically 
significant for α = 0.05.  Thus we conclude that iron release by NTA in the presence of 
MDS is best described as a combination of saturation and first-order pathways.  It is 
presumed that this change from strictly first order kinetics to a combination of saturation 
and first order kinetics is related to the binding to the MDS to the KISAB site of the 
protein and increasing the rate of the closed-to-open conformational change in the 
protein.  
 
Table 4.3  
Rate Parameters for Iron Release from C-Terminal Monoferric Transferrin in the 
Presence and in the Absence of MDS 
 kmax (min-1) x 103 kd  x 103 (M) k` x 103 (M-1min-1) σy 
NTA - - 0.32 ± 0.01 0.0006
NTA+75mMa MDS 71 + 4 45 + 7 - 0.0025
NTA+75mMb MDS 42 + 10 22 +  8 0.14 + 0.05b 0.0021
aParameters from fit to equation (4.1) 
bParameters from fit to equation (4.5) 
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4.3 
Discussion 
It has been well established iron removal by many ligands shows simple 
saturation behavior with respect to the ligand concentration (1;2;19-21).  This behavior is 
described by equation 4.1.  Bates and co-workers (1) were the first to report this behavior 
and proposed the mechanism shown in equations (4.2) – (4.4), in which saturation 
kinetics result from a rate-limiting conformational change in the protein.  In the Bates 
mechanism, each lobe of ferric transferrin exists in a mixture of open and closed forms, 
with iron release occurring only from the open form.  If one assumes steady state 
concentrations of the intermediate species Fe-CO3-Tf* (equation 4.2) and AHA-Fe-CO3-
Tf* (equation 4.3), then the kmax parameter in equation 4.1 is equal to k1, the  rate constant 
for the conversion of the protein from the closed to the open form in equation 4.2. 
The Bates proposal of a gating conformational change has been reinforced by 
subsequent reports of the crystal structures of apo- and holotransferrin, which show that 
the removal of iron results in a very large conformational change.  Upon the removal of 
iron, there is a hinge movement that opens the cleft between the two domains in each 
lobe of the protein by approximately 63 degrees (22).  One can view the crystal structure 
of ferric transferrin as a reasonable representation of the closed form.  The “open” form 
proposed by Bates would presumably correspond to some intermediate conformation 
along the reaction pathway between ferric transferrin and the fully open conformation of 
apotransferrin.  The precise degree to which the protein conformation must change in 
order to enable attack of the chelating agent and the effective removal of iron has not 
been established. 
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It has been known for some time that a variety of simple inorganic anions can 
alter the rates of iron release by various chelating agents.  It is important to note that these 
kinetic effects do not correlate well with simple changes in ionic strength of the solution.  
Nor do they correlate well with the general lyotropic effects of the anions.  The 
Hoffmeister series describing general anion affects on protein structure is (23;24) 
 
            CO32- < SO42- < H2PO4- < F- < Cl- < Br- ~ NO3- < I- < ClO4- < SCN- 
 Less denaturation     more denaturation 
 
The precise effect of anions on the rates of iron release depends to some degree on the 
choice of the chelating agent used to remove the iron.  As an example, the effect of 
anions on the first order component for iron release by PPi is (3) 
 
   SCN- < F- ~ NO3- < Cl- ~ HCO3- < SO42- < ClO4- 
  Slower iron release            faster iron release  
 
One would expect that those anions that promote denaturation would have the 
greatest impact on terms of enhancing the rate of iron release to a LWM chelating agent.  
However, there is a very poor correlation between the Hoffmeister series and the ability 
of anions to accelerate the rate of iron release.  Thus it is widely accepted that the 
transferrin molecule has one (or more) specific binding site(s) for the allosteric anions, 
which is typically referred to as the kinetically significant anion binding site, or the 
KISAB site. 
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The new data reported here in Figure 4.3 confirms that the allosteric anion can 
exert its impact not by drastically changing the mechanism of iron release, but by 
changing the kmax and kd parameters associated with the Bates conformational change 
mechanism.  Thus one can regard iron release as proceeding from two transferrin 
populations that are linked by an anion binding equilibrium.  Such a model was proposed 
much earlier by Bertini et al. (4).  Their original kinetic model can be simplified and 
expressed as an expansion of equation (4.1) as  
 
  
'
max max
'
[ ] [ ] [ ]1
[ ] 1 [ ] [ ] 1 [ ]
A
obs
d A d A
k L k L K Ak
k L K A k L K A
⎛ ⎞ ⎛ ⎞= +⎜ ⎟ ⎜ ⎟+ + + +⎝ ⎠ ⎝ ⎠
  (4.7) 
 
where the parameters kmax and kd refer to the “native” protein structure and the 
parameters kmax’ and kd’ refer to an alternative conformation as modified by binding of 
the anion (A) to the KISAB site, and KA is the anion-protein binding constant.  The terms 
in parenthesis simply partition the overall protein population into the fraction existing in 
the native structure and the fraction in the modified structure. 
The results reported here on the effects of sulfonate anions on iron release by 
AHA and deferiprone consistently show a simple linear dependence of kobs on the anion 
concentration.  Equation (4.7) can explain this linear dependence, but only under rather 
restricted conditions.  One must assume that anion-binding is weak, so that KA[A] <<  1 
for all anion concentrations studied.  Under these conditions, and at a fixed concentration 
of ligand, the dependence of kobs on the anion concentration reduces to 
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                                          mod [ ]obs native Ak k k K A= +                                            (4.8) 
 
where knative  is the observed rate constant at the specified ligand concentration for the 
native form of the protein, and kmod is the corresponding rate constant at the same ligand 
concentration for the allosterically modified form of the protein.  From linear plots, it is 
impossible to deconvolute individual values for kmod  and KA.  Our experiments involved 
anion concentrations of up to 100 mM.  If we assume that this produces only 10% 
saturation of the anion binding sites, so that the plots remain linear, this would put an 
upper limit on KA of ~1.  One could speculate that this very low binding affinity reflects a 
process in which a more favorable ∆G for anion binding is largely offset by an 
unfavorable ∆G for a concomitant protein conformational change.  One should also note 
that since the slopes of the plots in Figures 4.1 and 4.2 are related to the product of 
kmodKA, it is impossible to tell whether the greater efficacy of the disulfonates in 
promoting iron release is a result of a larger kmod for iron release or a larger KA for anion 
binding. 
 In principle one could continue to measure kobs at higher anion concentrations 
until one observes sufficient curvature in the plot to determine individual values of kmod 
and KA.  However, we felt that to do so would require anion concentrations so large that 
non-specific salt effects were highly likely to confuse and/or mask the specific allosteric 
effects associated with anion binding at the KISAB site. 
 Others have proposed that the KISAB site must be occupied by some anion in 
order for any iron release to occur (25).  In this model, the anion-binding reaction 
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referred to above would actually represent the partial displacement of an original anion 
from the buffer by the added sulfonate.  Other than treating KA as an anion exchange 
equilibrium rather than a simple anion binding equilibrium, the form of equation (4.7) 
would remain the same. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Variation in kobs for iron removal from C-terminal monoferric 
transferrin by 200 mM AHA as a function of the ionic strength of the solution.  The 
ionic strength of the 100 mM Hepes buffer is 0.041.  Ionic strength was increased by 
adding either SMS or MDS. 
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 Evaluating the rates of iron removal as a function of ionic strength was not an 
original objective of this study.  Nevertheless, one can use the data shown in Figure 4.1 to 
prepare a plot of the rate constant for iron release by 200 mM AHA as a function of the 
ionic strength, as shown in Figure 4.7.  The plots for MDS and SMS both extrapolate 
back to a rate constant of about 0.01 min-1 at zero ionic strength.  These data would argue 
that there is small, but non-zero rate of iron release even when the KISAB site is not 
occupied. 
The Bates mechanism is sufficient to describe iron removal by ligands such as 
deferiprone, AHA, and LICAMS that follow simple saturation kinetics (1;2;19;20).  
However, there are a number of ligands for which the rates of iron release are described 
by equation (4.5), with a combination of saturation and first-order components.  These 
include PPi (3-5;26), a series of aminophosphonic acids (e.g. 
nitrilotris(methylenephosphonic acid) (3;5;11), and a series of phosphonocarboxylic 
acids (e.g. phophonoacetic acid) (27;28).  Although conformational gating is widely 
accepted as the basis for the saturation component of iron release, there is no consensus 
on the origin of the first order component. 
Previous studies on iron removal by NTA and DTPA have shown that kobs has a 
simple first-order dependence on the ligand concentration.  The absence of any element 
of saturation kinetics for NTA and DTPA is puzzling.  There is no obvious reason why 
these ligands should not be able to rapidly remove iron from the proposed open 
conformation of ferric transferrin.  One possible explanation for a negligible kmax value 
for NTA is that the anionic carboxylate functional groups of NTA bind at the KISAB site 
and reduce the value of kmax.  We evaluated the effect of acetate on the rates of iron 
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release by AHA.  As shown in Table 4.1, the presence of acetate causes only a small 
acceleration in the rate of iron release.  In addition, EDTA and citrate both have easily 
detectable kmax values.  Thus it seems unlikely that the acetate groups of NTA could be 
responsible for the dramatically lower kmax value for NTA. 
The previous explanation for first-order kinetics was that iron release by NTA 
was described by equation (4.2), but the kmax value for the saturation component was so 
low that it could not be detected against the background of faster iron release via the first-
order pathway (11).  This interpretation for iron release by NTA is supported by the 
present results.  The addition of 50 mM MDS increases the value of kmax for iron removal 
by AHA by a factor of 4, from 0.016 min-1 to 0.072 min-1.  This rate parameter is 
presumed to represent the forward rate constant for the transition from the closed to the 
open protein conformation.  As one would then expect, the addition of MDS increases the 
kmax for iron release by NTA from its previous negligible value to 0.042 min-1. 
The addition of MDS reveals the saturation component for iron release by NTA, 
but it does not eliminate the first-order component for iron release.  The results for iron 
release in the presence of 75 mM MDS show that the sulfonate anion decreases the k’ 
value for iron release by NTA by about 50%, from 0.32 M-1 min-1 to 0.14 M-1min-1.  Thus 
the general observation is that anion binding at the KISAB site substantially enhances 
iron release via the saturation pathway, but modestly reduces iron release via the first 
order pathway. 
It would be possible to observe an apparent first-order process for iron release due 
to the binding of anions to the KISAB site.  We previously reported such an example 
involving a comparison of iron release rates for two solutions of deferiprone, one 
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prepared from the free base and one prepared from the deferiprone hydrochloride salt (2).  
In the latter case, the increase in the Cl- concentration that accompanied each increase in 
the deferiprone concentration led to a linear increase in the rate constant, whereas 
experiments using the free base showed simple saturation kinetics.  This result would be 
consistent with equation (4.8), with Cl- occupying the anion binding site. 
It is possible that the anionic carboxylate groups of NTA could bind to the KISAB 
site and increase the kmax for iron release by allosteric effects as the NTA concentration is 
increasing, and that this could account for the apparent first-order dependence on the 
NTA concentration.  However, the data reported here do not support such a model.  We 
have examined the effect of acetate groups as KISAB allosteric anions.  The addition of 
100 mM acetate accelerates iron release by AHA by only about 25%, from 0.016 to 0.020 
min-1.  To account for the linear component of iron release by NTA, the acetate groups 
would have to enhance kmax from essentially zero (upper limit of ~0.002) by a factor of at 
least 20 to about 0.03 min-1 at 100 mM NTA.  It seems unlikely that the weakly allosteric 
acetate group could account for a 20-fold increase.  
Others (25) have proposed that the first-order component is basically an artifact 
that is produced as the changes in the ionic strength of the solution and this causes a 
gradual change in the kmax value of the conformational change.  However, it is quite clear 
that the kinetic effect of anions is not related to changes in ionic strength.  Marques et al. 
have shown that selective anion effects on the rates persist, even when ionic strength is 
held constant (13).  In addition, Brook et al. (28) have shown that the first-order term for 
iron removal by PPi disappears for tripolyphosphate, which removes iron by a simple 
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saturation process, even though it would have a larger impact on any changes in ionic 
strength.   
 Another proposal is that the first-order component for iron release represents a 
different reaction pathway that is independent of the gating conformational change, and 
that this pathway involves the replacement of the synergistic carbonate anion to form a 
Fe-ligand-Tf ternary intermediate (29).  The data presented here on the effects of MDS 
are consistent with two distinct pathways for iron release.  The dianion increases the kmax 
value for both AHA and NTA, while resulting in a slight reduction in the k’ value for 
NTA. 
 Despite considerable work on the effects of anions on iron removal, the location 
of the KISAB site has not been established.  Previous computational studies identified 
several possible sites, but did not establish a clear choice among the possible locations 
(16).  The data reported here that disulfonates are more effective KISAB anions than 
monosulfonate and methanedisulfonate should provide additional information to help 
identify the site. 
 Sulfonic acids accelerate the rate of iron release from C-terminal monoferric 
transferrin.  This presumably reflects their ability to bind to the KISAB site on 
transferrin.  The consistent difference between the mono- and disulfonates suggests that 
the KISAB site is sufficiently complex and structured to allow it to interact with both 
functional groups of the disulfonates.  Binding of the disulfonates increases the kmax value 
for the saturation pathway.  For NTA, this increase reveals a saturation pathway that was 
not observable for iron release in the absence of the anions.  In contrast to the large 
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increase in kmax for the saturation pathway, there is a slight decrease in the k’ value for 
iron release by NTA via the first-order pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.110 
 
110 
 
 
References 
 
 1.  Cowart, R. E., Kojima, N., and Bates, G. W. (1982) J. Biol. Chem. 257, 7560-
7565. 
 2.  Li, Y. and Harris, W. R. (1998) Biochim. Biophys. Acta 1387, 89-102. 
 3.  Harris, W. R. and Bali, P. K. (1988) Inorg. Chem. 27, 2687-2691. 
 4.  Bertini, I., Hirose, J., Luchinat, C., Messori, L., Piccioli, M., and Scozzafava, A. 
(1988) Inorg. Chem. 27, 2405-2409. 
 5.  Harris, W. R., Rezvani, A. B., and Bali, P. K. (1987) Inorg. Chem. 26, 2711-2716. 
 6.  Bali, P. K. and Harris, W. R. (1990) Arch. Biochem. Biophys. 281, 251-256. 
 7.  Marques, H. M., Egan, T. J., and Pattrick, G. (1990) South African Journal of 
Science 86, 21-24. 
 8.  Harris, W. R., Bali, P. K., and Crowley, M. M. (1992) Inorg. Chem. 31, 2700-
2705. 
 9.  Egan, T. J., Ross, D. C., Purves, L. R., and Adams, P. A. (1992) Inorg. Chem. 31, 
1994-1998. 
 10.  Marques, H. M., Walton, T., and Egan, T. J. (1995) J. Inorg. Biochem. 57, 11-21. 
 11.  Bali, P. K., Harris, W. R., and Nesset-Tollefson, D. (1991) Inorg. Chem. 30, 502-
508. 
 12.  Baldwin, D. A. and De Sousa, D. M. R. (1981) Biochem. Biophys. Res. Commun. 
99, 1101-1107. 
 13.  Marques, H. M., Watson, D. L., and Egan, T. J. (1991) Inorg. Chem. 30, 3758-
3762. 
 14.  Nurizzo, D., Baker, H. M., He, Q. Y., MacGillivray, R. T. A., Mason, A. B., 
Woodworth, R. C., and Baker, E. N. (2001) Biochemistry 40, 1616-1623. 
 15.  He, Q. Y., Mason, A. B., Tam, B. M., MacGillivray, R. T. A., and Woodworth, R. 
C. (1999) Biochemistry 38, 9704-9711. 
 16.  Amin, E. A., Harris, W. R., and Welsh, W. J. (2004) Biopolymers 73, 205-215. 
 17.  Baldwin, D. A. (1980) Biochim. Biophys. Acta 623, 183-198. 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.111 
 
111 
 
 18.  He, Q. Y., Mason, A. B., Nguyen, V., MacGillivray, R. T., and Woodworth, R. C. 
(2000) Biochem. J. 350, 909-915. 
 19.  Carrano, C. J. and Raymond, K. N. (1979) J. Am. Chem. Soc. 101, 5401-5404. 
 20.  Kretchmar Nguyen, S. A., Craig, A., and Raymond, K. N. (1993) J. Am. Chem. 
Soc. 115, 6758-6764. 
 21.  Turcot, I., Stintzi, A., Xu, J., and Raymond, K. N. (2000) J. Biol. Inorg. Chem. 5, 
634-641. 
 22.  Jeffrey, P. D., Bewley, M. C., MacGillivray, R. T. A., Mason, A. B., Woodworth, 
R. C., and Baker, E. N. (1998) Biochemistry 37, 13978-13986. 
 23.  Zhang, Y., Furyk, S., Bergbreiter, D. E., and Cremer, P. S. (2005) J. Am. Chem. 
Soc. 127, 14505-14510. 
 24.  Zhang, Y. and Cremer, P. S. (2006) Curr. Opin. Chem. Biol. 10, 658-663. 
 25.  Kretchmar, S. A. and Raymond, K. N. (1988) Inorg. Chem. 27, 1436-1441. 
 26.  Bali, P. K. and Harris, W. R. (1989) J. Am. Chem. Soc. 111, 4457-4461. 
 27.  Harris, W. R., Brook, C. E., Spilling, C. D., Elleppan, S., Peng, W., Xin, M., and 
Wyk, J. V. (2004) J. Inorg. Biochem. 98, 1824-1836. 
 28.  Brook, C. E., Harris, W. R., Spilling, C. D., Peng, W., Harburn, J. J., and Srisung, 
S. (2005) Inorg. Chem. 44, 5183-5191. 
 29.  Harris, W. R. (1984) J. Inorg. Biochem. 21, 263-276. 
 
 
 
 
 
 
 
 
 
 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.112 
 
112 
 
Chapter 5  
 
Effect of Phosphonate and Phosphonocarboxylate Anions on Saturation and First 
order Kinetic Pathways of Iron Release from Transferrin 
 
5.1 
Introduction 
 This chapter is in continuation with our attempt to have a better understanding of 
the effects of allosteric anions on the saturation and first order pathways of iron release.  
In Chapter 4, a series of sulfonates with one or two anionic functional groups were 
studied for their effect on the first order and saturation pathways of iron release.  The 
interesting results obtained inspired us to extend our study to a different series of anions, 
the phosphonates and phosphonocarboxylates. 
 
5.1.1 
Kinetic pathways for iron removal  
 Kinetic studies on iron removal from transferrin by a variety of chelating agents 
have been performed.  Different mechanisms have been proposed on the basis of the 
order of the reaction with respect to the ligand concentrations.  The rate of iron release 
from transferrin by a number of ligands shows saturation with respect to the ligand 
concentration.  Bates explained this kinetic behavior on the basis of a rate limiting 
conformational change in the protein (1).  Acetohydroxamic acid (AHA) and deferiprone 
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are two such ligands that follow saturation kinetics (1;2).  The ligand dependence on the 
rate is described by equation (5.1). 
 
 
                                                                                                                         (5.1) 
 
Saturation is usually attributed to a rate limiting conformational change in the protein 
according to the mechanism proposed by Bates and co-workers (1).  In this mechanism, 
kmax, the rate constant under saturating concentrations of the ligand, represents the rate of 
a conformational change from a closed form of ferric transferrin to a more reactive open 
form of the protein. 
 Not all ligands studied so far follow the Bates mechanism.  Many ligands, such as 
pyrophosphate (PPi) (3-5) and phosphonic acids (6-10), show a more complex ligand 
dependence.  They appear to follow saturation kinetics at low ligand concentrations, but 
the rate continues to increase linearly with increasing concentrations of the ligand.  This 
kind of kinetic behavior is described by equation (5.2), where the first term represents a 
saturation component and the second term represents a first-order component.  
 
                                                                                                                    (5.2) 
  
 A third type of kinetic behavior is observed for iron removal by the simple 
aminocarboxylic acids nitrilotriacetic acid (NTA) and diethylenetriaminepentaacetic acid 
(DTPA).  Iron removal by these ligands shows a simple first order dependence on the 
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ligand concentration (6;11).  It has been proposed that for iron removal by these ligands, 
the kmax values are so small that equation (5.2) reduces to a simple first-order dependence 
on the ligand concentration.  
 Nonsynergistic anions affect the rate of iron release, but the effect varies for the 
two lobes of the protein and for different chelating agents.  For example, chloride at pH 
7.4 increases the rate of iron release from C-terminal monoferric transferrin by 
ethylenediaminetetraacetic acid (EDTA), but slows the rate of iron release from N-
terminal monoferric transferrin (12;13).  For iron release by citrate, chloride increases the 
rate for both C- and N- monoferric transferrins (14).  Lastly, for iron release by 
pyrophosphate, chloride increases the rate for C-terminal monoferric transferrin and has 
no effect on the rate of iron from N-terminal monoferric transferrin (10;15).  It has been 
proposed that these variable anion effects on the rates of iron release reflect the binding 
of the anions to an allosteric binding site known as the Kinetically Significant Anion 
Binding (KISAB) site (14).  However, the exact location or the structure of this proposed 
anion binding site has not been established (16-18). 
 We have proposed that for complex kinetic systems described by equation (5.2), 
the first term reflects iron release via the Bates conformational change mechanism, while 
the second term reflects iron release via an alternative reaction pathway that is not 
restricted by a rate limiting conformational change (8;9;19).  However, others have 
proposed that the appearance of the first-order term arises when the ligand binds to the 
KISAB site and changes the value of kmax (4;14;15).  To help distinguish between these 
two possibilities, we are now attempting to evaluate how anionic ligands such as 
phosphonoacetic acid might act as an allosteric anion as well as an iron chelating agent 
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and to assess the degree to which it might alter its own rate of iron release by binding to 
the KISAB site.  To differentiate allosteric effects on the saturation and first order 
components of iron release, these studies use the chelating agents acetohydroxamate and 
deferiprone, which remove iron exclusively via a saturation process (1;2), and NTA, (6) 
which removes iron exclusively via a first order process.   
 In Chapter 4 we have reported the effect of a series of sulfonates on the rates of 
iron release by these ligands.  The sulfonates accelerate iron release via the saturation 
component and decrease the rate of iron release via the first order component.  This 
Chapter reports a continuation of these studies using two different classes of anions, 
diphosphonates and phosphonocarboxylates.  The primary difference from the sulfonate 
study in Chapter 4 is that some of these new anions are themselves good iron chelating 
agents.  This dual role of the chelating anions complicates the analysis of the kinetic data 
for iron release by mixtures of the anions and the reference chelating agents.  However, it 
allows us to address the issue of how an anionic chelating agent may also act as an 
allosteric anion to modulate the rate of its own iron removal. 
 
5.2. 
Results 
 The anions used in this study contain various combinations of carboxylate and 
phosphonate functional groups.  The focus is on bifunctional compounds, e.g. 
phosphonoacetic acid or methylenediphosphonic acid.  To provide a basis for assessing 
the degree to which the two functional groups in these compounds work cooperatively, 
the rates of iron release from C-terminal monoferric transferrin by 200 mM AHA have 
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been measured in the presence of the monofunctional anions methylphosphonate (MPA) 
and acetate.  The rate constants for iron release by AHA in the presence of 100 mM 
concentrations of these anions are shown in Table 5.1. 
 
Table 5.1 
Effect of methylphosphonate and acetate anions on the rate of iron removal by  
200 mM AHAa 
 kobs (min-1) x 103 
200 mM [AHA] 16.2 + 0.4 
[AHA] + 100 mM  MPA 25.4 + 0.2 
[AHA] + 100 mM  Acetate 20.4 + 0.3 
 a0.1 M HEPES, pH 7.4, 25 ºC 
 
5.2.1  
Effects of phosphonocarboxylates on iron release by AHA  
 The rates of iron release by AHA in the presence of MPA, phosphonoacetic acid 
(PAA), and 3-phosphonopropionic acid (PPA) have been evaluated.  As reported 
previously, PAA is a good iron chelating agent that removes iron from transferrin with a 
combination of saturation and first order components (20;21).  Although PPA contains 
the same two metal-binding functional groups, the simultaneous coordination of both 
groups forms a thermodynamically unstable 7-membered chelate ring.  Control 
experiments confirmed that over the concentrations used in these studies, neither PPA nor 
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MPA removes any significant amount of iron.  Thus PPA and MPA are treated as non-
complexing allosteric anions.   
 Rates of iron release by 200 mM AHA were measured in the presence of 
increasing concentrations of PPA and MPA.  To minimize the effects of day-to-day 
variations in the data, reactions with and without the added anion were always run 
simultaneously.  Both of these anions increase the rates of iron release by AHA.   This 
increase is represented as shown in equation (5.3),
 
                                                
'
% 100obs obs
obs
k kk x
k
−Δ =                                             (5.3) 
where kobs is the rate for AHA alone, and k’obs is the rate for AHA in the presence of the 
anion.  Plots of %∆k vs [anion] are shown in Figure 5.1.  
 The values of %Δk increase linearly with the anion concentration for both MPA 
and PPA.  The slope of the plot for PPA is greater than that for MPA.  The effect of 100 
mM PPA is greater than the sum of the effects of equimolar concentrations MPA alone 
and acetate alone.  Thus, the two functional groups of PPA appear to act cooperatively, 
presumably by binding more strongly to the transferrin. 
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Figure 5.1.  Plots of %Δk for the removal of iron from C-terminal monoferric 
transferrin by 200 mM AHA in the presence of methanephosphonate (MPA) and 3-
phosphonopropionic acid (PPA) and phosphonoacetamide (PAM) at 25 ºC in  
0.1 M Hepes, pH 7.4. 
 
 The “anion” PAA is also a good iron chelating agent (20;21).  The rates of iron 
release by PAA alone and its methyl and ethyl derivatives have been evaluated in Chapter 
3, and they show a combination of saturation and linear kinetics.  We evaluated the effect 
of the anion PAA on iron release by AHA by measuring the rate constants for iron release 
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by AHA alone, by PAA alone, and by a mixture of AHA and PAA.  To minimize day-to-
day variations in the data, these experiments were run by taking the same stock solution 
of C-terminal monoferric transferrin, preparing the three kinetic samples, and running the 
reactions simultaneously using a rotating 4-position cuvette holder in the fluorimeter.  
The apparent rate constant for iron release by AHA in the presence of PAA was 
calculated as shown in equation (5.4) 
 
                         ݇௔௣௣ሺܣܪܣሻ ൌ  ݇௢௕௦ሺܣܪܣ ൅ PAܣሻ െ ݇௢௕௦ሺPAܣሻ                         (5.4) 
 
In these experiments, the concentration of AHA was held constant at 200 mM.  Figure 
5.2 shows the values of kobs for the samples with PAA alone and the mixture of PAA and 
AHA.  The kobs value for AHA alone was consistently 0.016, so these data are not shown 
in Figure 5.2.  
 The apparent rate constant (kapp) for the removal of iron by AHA in the presence 
of PAA was obtained by subtracting the rate constant for the AHA/PAA mixture from the 
matched sample of PAA alone.  As shown in Figure 5.2, the value of kapp is constant for 
all PAA concentrations, with an average value of 0.008 + 0.002 min-1.  This is 50% of the 
kobs for AHA in the absence of PAA.  In contrast to the allosteric effects of MPA and 
PPA, which significantly accelerate the rate of iron release by AHA, PAA appears to 
slow the release of iron by AHA. 
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Figure 5.2.  Plots of kobs for the removal of iron from the C-terminal monoferric 
transferrin by varying concentrations of phosphonoacetic acid (PAA) and by 
mixtures of 200 mM AHA with variable concentrations of PAA at 25 °C in 0.1 M 
Hepes, pH 7.4.  The kapp value for AHA is calculated as shown in equation (5.4). 
 
 The most obvious difference between PAA and PPA is the ability of PAA to form 
a more stable 6-membered chelate ring.  This suggests that the variations in the kinetic 
effects of PAA and PPA are related to their different iron-binding affinities.  To test this 
hypothesis, we conducted additional studies using phosphonoacetamide (PAM).  The 
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conversion of the free acetate group of PAA to an amide essentially destroys the ability 
of PAM to chelate iron, so that PAM cannot remove iron from transferrin and can act 
only as an allosteric anion.  Rates of iron release by AHA in the presence of increasing 
concentrations of PAM were measured.  The data were used to calculate values for %Δk 
as per equation (5.3), and the results are shown in Figure 5.1.  The conversion of the 
acetate to an amide fully restores the positive allosteric effect seen for PPA.  
 The effect of phosphonocarboxylates on iron removal by deferiprone has also 
been measured.  The effects of the allosteric anions MPA, PAA, PPA, and PAM on iron 
release by deferiprone have been determined as described above for the studies which 
used AHA as the reference ligand.  The variations in the rate constants for deferiprone 
have been converted to values of %∆k and plotted in Figure 5.3.  The results are 
essentially the same as those observed for iron removal by AHA.  The non-chelating 
anions MPA, PPA, and PAM all accelerate iron removal, while the chelating anion PAA 
retards the rate of iron removal by deferiprone. 
 
 
 
 
 
 
 
 
 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.122 
 
122 
 
[Anion]
0 20 40 60 80 100 120
%
 Δk
 
-100
-50
0
50
100
150
200
MPA
PAM
3-PPA
PAA
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  Plots of %Δk for the removal of iron from the C-terminal monoferric 
transferrin by 20 mM deferiprone (L1) in the presence of methane phosphonate 
(MPA), phosphonoacetic acid (PAA), 3-phosphonopropionic acid (PPA) 
phosphonoacetamide (PAM) at 25 °C in 0.1 M Hepes, pH 7.4. 
 
5.2.2 
Effect of excess bicarbonate on inhibition by PAA. 
 Since the inhibition of iron release by PAA appears to be linked to its ability to 
bind Fe3+, we considered the possibility that the PAA might replace the synergistic 
carbonate anion to form an Fe-PAA-Tf ternary complex that reacts more slowly than the 
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original Fe-CO3-Tf complex with AHA.  If this were true, the addition of excess 
carbonate to the solution should reduce the degree of formation of the Fe-PAA-Tf 
complex and thus should reduce the inhibitory effect of the PAA.   
 In addition to its well-known role as the synergistic anion for the formation of the 
normal Fe-CO3-Tf ternary complex (22), bicarbonate might also act as an allosteric anion 
and bind to the KISAB site.  Therefore, an additional set of experiments were conducted 
to measure the rates of iron release by both PAA and AHA in solutions with bicarbonate 
concentrations of 0, 1, 5, 15, and 20 mM to measure the degree to which bicarbonate acts 
as a KISAB anion to alter the rates of iron release.  A linear extrapolation was used to 
calculate the rate constant for iron removal by PAA and AHA at 25 mM bicarbonate.  
The rate constant for iron release by PAA was essentially unaffected by excess 
bicarbonate, with a rate constant of 0.0212 min-1 at both 0 and 25 mM bicarbonate.  The 
rate of iron release by AHA changed from 0.0107 min-1 with no bicarbonate to 0.0168 
min-1 at 25 mM bicarbonate.   
 The rate constant for iron release for a solution containing a mixture of 
AHA/PAA/carbonate was determined to be 0.0287 min-1, which is presumed to be the 
sum of the rate constant for PAA and the apparent rate constant for AHA.  If one 
subtracts the value of 0.0212 min-1 for iron removal by PAA, the apparent rate constant 
for AHA is 0.0075 min-1, or 45% of the value for AHA in the presence of 25 mM 
bicarbonate.  This is essentially identical to the degree of inhibition by PAA on iron 
release by AHA at ambient carbonate.  Thus it appears that the inhibition by PAA on the 
rate of iron removal by AHA does not involve the displacement of the synergistic 
carbonate anion. 
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5.2.3. 
Effect of phosphonocarboxylates on kmax and kd for iron removal by AHA. 
 The ligand dependence of iron removal by AHA has been described by equation 
(5.1).  The change in kobs for iron removal by AHA produced by PAA and PPA (Figure 
5.1) could be due either to changes in kmax, changes in kd, or to some combination of 
both.  To distinguish among these possibilities, kobs values were measured for iron 
removal by varying concentrations of AHA, both in the absence and in the presence of a 
constant concentration of either 50 mM PPA or 5 mM PAA.  Since the inhibition by PAA 
is essentially constant for concentrations of PAA > 5 mM, a lower concentration of PAA 
was chosen so that the overall rate of iron release for the mixture would be due mainly to 
iron release by AHA.  
 Plots of kobs vs [AHA] for AHA alone, AHA + 5 mM PAA, and AHA + 50 mM 
PPA are show in Figure 5.4.  Each set of data has been fit both to equation (5.1), which 
describes simple saturation kinetics, and to equation (5.2), which described a combination 
of saturation and linear kinetics.  It is clear from inspection that equation (5.2) gives a 
better fit to the data when either PPA or PAA is present.  For the data on iron release by 
AHA alone, the fits of equation (5.1) and equation (5.2) are very similar.  An R-factor 
ratio test (23) indicates that the improvement in the fit for equation (5.2) is statistically 
significant at α = 0.05.  The rate parameters obtained from the fit of the data in Figure 5.2 
to equation (5.2) are shown in Table 5.2 
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Table 5.2 
Rate parameters for the release of iron from C-terminal monoferric transferrin by AHA 
alone and in combination with either 5 mM PAA or 50 mM PPA 
 103kmax (min-1) kd (mM) 103k’ (M-1min-1) σya 
AHA alone 13.6 + 1.3 59 + 10 0.0102 + 0.026 0.0004 
AHA + PPA 16.8 + 0.7 8.0 + 1.1 0.0307 + 0.026 0.0007 
AHA + PAA 4.3 + 0.6 10 + 5 0.0213 + 0.022 0.0005 
aStandard deviation in the fit of of kobsvs [AHA] to equation (5.2) 
 
 Both PPA and PAA cause a significant decrease in kd for iron removal by AHA, 
such that the reaction approaches saturation at lower AHA concentrations.  Since PPA 
also increases the kmax value, the net result is a significant increase in the rate or iron 
release at low AHA concentrations.  In contrast, PAA reduces kmax, so that even though 
this system reaches saturation quickly, the rate of iron release is lower than that for AHA 
alone. 
 Previous studies have reported that iron release by AHA follows simple saturation 
kinetics (2).  Thus the most unexpected result from Figure 5.4 is that AHA may have a 
small, but statistically significant, first-order component for iron release.  Both PAA and 
PPA result in a significant increase in the first order process, so that iron release in the 
presence of these anions must be described as complex kinetics with both saturation and 
first-order components. 
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Figure 5.4.  Plots of kobs for the removal of iron from C-terminal monoferric 
transferrin by acetohydroxamic acid (AHA), AHA in the presence of 50 mM 3-
phosphonopropinonic acid (PPA) and AHA in the presence of 5 mM 
phosphonoacetic acid (PAA) at 25 °C in 0.1 M Hepes pH 7.4. 
 
5.2.4 
Effects of phosphonocarboxylates on iron release by NTA 
 The rate of iron release from transferrin is first order with respect to the 
concentration of NTA (6).  To study the effect of phosphonocarboxylates, on the first 
order component for iron release the rate of iron release from C-terminal monoferric 
transferrin by NTA was measured in the presence of increasing concentrations of MPA, 
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PAA and PPA.  Both MPA and PPA behaved as a simple anion without removing any 
iron on their own, and their effect on the rate of iron release by NTA was calculated as 
%∆k as shown in equation (5.3).  Since PAA is a good chelating agent and does remove 
iron, the apparent rate constant for iron release by NTA was calculated as shown in 
equation (5.4).  This apparent rate constant was then used to calculate %∆k for PAA.  
Plots of %∆k vs [anion] are shown in Figure 5.5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  Plots of %Δk for the removal of iron from C-terminal monoferric 
transferrin by 100 mM nitrilotriacetic acid (NTA) in the presence of 
methanephosphonate (MPA), phosphonoacetic acid (PAA), 3-phosphonopropionic 
acid (PPA) at 25 ºC in 0.1 M Hepes, pH 7.4. 
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 The effects of MPA, PAA, and PPA on the rates of iron removal by NTA are 
qualitatively similar to their effects on iron removal by AHA.  Both MPA and PPA 
increase the rates of iron removal, but the increases for NTA are much smaller, ~20%, 
compared to 200% acceleration for iron release by AHA and deferiprone.  The presence 
of PAA decreases the rate or iron removal for NTA by about 40%, which is comparable 
to its effect on iron release by AHA.  However, the inhibition of NTA requires slightly 
high concentrations of PAA. 
 
5.2.5 
Effect of phosphonocarboxylates on kmax, kd, and k’ for NTA 
 Rates of iron release by various concentrations of NTA were measured using 
samples of C-terminal monoferric transferrin that all contained 50 mM PPA.  The plot of 
kobs vs [NTA] is shown in Figure 5.6 for samples with and without the PPA.  At 
concentrations of NTA < 50 mM, the iron removal reaction does not go to completion, 
and the values of kobs were calculated using equation (2.3) from Chapter 2 to fit the 
intensity vs time data.  The data in the absence of PPA confirm that iron release by NTA 
is a simple pseudo first-order process, with an observed rate constant of 0.33 + 0.01 M-1 
min-1.  This is essentially identical to the value of k’ = 0.32 + 0.03 M-1min-1 published 
previously (6). 
 The addition of PPA dramatically changes the ligand dependence of iron removal 
by NTA.  The reaction is clearly no longer a simple first-order process.  The data on iron 
removal in the presence of the PPA have been fit to both equation (5.1) and equation 
(5.2), and the resulting parameters are shows in Table 5.3.  As one would expect from 
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inspecting Figure 5.6, there is a highly significant improvement in the fit for equation 
(5.2), as shown by the decrease in σy from 0.0029 to 0.0008.  Thus we can conclude that 
iron release by NTA in the presence of 50 mM PPA is best described as complex 
kinetics, representing a combination of saturation and first-order pathways.  
 The rate constants for iron release from C-terminal monoferric transferrin were 
also measured by varying concentrations of NTA in the presence 25 mM PAA.  For each 
experiment, the measured kobs value would reflect the total rate of iron release by both 
NTA and PAA.  The apparent rate constant for iron removal by NTA was calculated by 
subtracting the measured rate constant for 25 mM PAA (0.0223 min-1) from the total kobs 
value for each mixture to give the kapp for iron release by NTA in the presence of 25 mM 
PAA.  These kapp values are plotted in Figure 5.6. 
 The plot of the kapp values for NTA is essentially linear with a small y-intercept.  
It appears that there might be a slight curvature at low concentrations of NTA, and we 
attempted to fit the data to equation (5.2) for saturation-linear kinetics.  However, the 
correlations among the 3 adjustable parameters are extremely high, and the errors in the 
calculated parameters are all well over 100%.  Therefore, the data were fit to a simple 
linear function, with the assumption that the slope was equal to k’, and the y-intercept 
was equal to kmax.  The results are shown in Table 5.3. 
 
 
 
 
 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.130 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.  Plot of rate constant for the removal of iron from C-terminal 
monoferric transferrin at 25 ˚C in 0.1 M Hepes, pH 7.4 by varying concentrations of 
nitrilotriacetic acid (NTA), NTA in the presence of 50 mM 3-phosphonopropionic 
acid (PPA), NTA in the presence of 25 mM phosphonoacetic acid (PAA) and NTA in 
the presence of 5 mM MDP. 
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Table 5.3 
Rate parameters for iron release from C-terminal monoferric transferrin by NTA in the 
presence of selected anions. 
Anion 103 kmax (min-1)  kd  (mM)  103 k` (M-1min-1) σy 
None - - 0.325 ± 0.012  
50 mM PPAa 50 ± 4 32 ± 7 - 0.0029 
50 mM PPAb 19 ± 1 5 ± 1 0.200 ± 0.012 0.0008 
25 mM PAA 2.1 + 0.6 - 0.247 + 0.009 0.0014 
5 mM MDP 2.7 + 0.8 - 0.251 + 0.010 0.0014 
aData fit to equation (5.1) with two adjustable parameters 
bData fit to equation (5.2) with three adjustable parameters 
 
 Both PPA and PAA appear to give a similar reduction of ~30% in k’.  However, 
they have very distinct effects on kmax.  The addition of 50 mM PPA increases kmax for 
NTA from essentially zero to 0.050 min-1.  A very similar increase in kmax for NTA has 
been observed in the presence of methylenedisulfonic acid (MDS) in Chapter 4.  In 
contrast, the presence of PAA has little, if any, impact on kmax for iron removal by NTA.  
The linear fit gives a small non-zero intercept of 0.0021 + 0.006.  This value of kmax is 
more than three times its standard deviation, which suggests that the difference from a 
value of zero is statistically significant.  However, the kapp values are obtained by 
subtracting the rate constant for PAA from each value of kobs for the mixture of NTA and 
PAA.  The value of the intercept would correspond to an error of only 10% in the value 
used for the rate constant for PAA.  Thus the significance of the small kmax value for 
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NTA in the presence of PAA is not clear.  Whether or not kmax is slightly greater than 
zero, the major impact of PAA on the overall rate of iron release by NTA is the decrease 
in the k` value.  
 
5.2.6 
Effect of diphosphonates on iron removal by AHA  
 The effects methanediphosphonate (MDP) and ethanediphosphonate (EDP) on 
iron release by AHA have been evaluated.  The rates of iron release by MDP alone and 
mixtures of MDP with 200 mM AHA were measured and are plotted in Figure 5.7.  The 
mixtures show a consistent increase in kobs relative to the same concentration of MDP 
without AHA.  The kobs values for each mixture is assumed to be the sum of the rate 
constants for MDP and AHA.  At each concentration of MDP, the rate constant for MDP 
alone is subtracted from the rate constant for the mixture to obtain a value of kapp for 
AHA.  This value of kapp is used with the rate constant for AHA alone to calculate value 
of %∆k by use of equation 5.3. 
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Figure 5.7.  Plots of kobs for the removal of iron from the C-terminal monoferric 
transferrin by methanediphosphonate (MDP) and by the mixture of 200 mM AHA 
and MDP at 25 ºC, 0.1 M Hepes, pH 7.4.  The values of kapp represent the rate 
constant of the mixture minus the rate constant for MDP alone. 
 
 Values of %Δk vs [anion] for 200 mM AHA are plotted in Figure 5.8.  The data 
on the monophosphonate MPA shows the linear increase due to this non-chelating anion.  
The chelating MDP anion has a very different impact on iron release from AHA.  All 
concentrations of MDP that were test reduced the rate of iron release by AHA by 
approximately 50%.  This result is very similar to the rate reduction caused by PAA. 
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Figure 5.8.  Plots of %Δk for the removal of iron from C-terminal monoferric 
transferrin by 200 mM AHA in the presence of methanephosphonate (MPA), 
methanediphosphonate (MDP), ethanediphosphonate (EDP), at 25 ºC in 0.1 M 
Hepes, pH 7.4. 
 
 We also studied the effect of the longer diphosphonate, EDP, on the rate of iron 
removal by AHA.  Rates of iron release were measured for paired samples that contained 
increasing concentrations of EDP, with and without 200 mM AHA.  At low 
concentrations, EDP fails to remove any appreciable amount of iron, so the observed rate 
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constants were due entirely to iron removal by AHA.  However, EDP concentrations 
greater than 25 mM remove appreciable amounts of iron in the absence of AHA.  Thus 
for higher concentrations of EDP, the apparent rate constant for AHA was obtained by 
subtracting the rate constant for iron removal by EDP from the observed rate constant of 
the AHA/EDP mixture. 
 Values of %∆k for EDP are also plotted in Figure 5.8.  The results for EDP are 
more complex than those observed for any other anion.  At low concentrations, EDP 
behaves as a typical non-chelating anion and increases the rate constant for AHA just as 
MPA does.  However, as soon as the concentration of EDP reaches a level sufficient to 
remove iron from transferrin, its behavior changes to the same inhibitory effect as that 
observed for MDP.  Thus high concentrations of EDP inhibit iron release by AHA by 
about 50%. 
 
5.2.7 
Effects of diphosphonates on iron release by NTA  
 The effects of MPA, MDP, and EDP on iron release by NTA were also evaluated, 
and the resulting %∆k values are plotted in Figure 5.9.  The results can be compared with 
the data on phosphonocarboxylates that are shown in Figure 5.5.  The MDP mimics the 
behavior of PAA and inhibits iron release by NTA by about 40%.  Low concentrations of 
EDP behave similarly to MPA and also accelerate iron release, but high concentrations of 
EDP mimic MDP and inhibit iron release by NTA. 
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Figure 5.9.  Plots of %Δk for the removal of iron from C-terminal monoferric 
transferrin by 100 mM nitrilotriacetic acid (NTA) in the presence of 
methanephosphonate (MPA), methanediphosphonate (MDP) and 
ethanediphosphonate (EDP) at 25 ºC in 0.1 M Hepes, pH 7.4. 
 
5.2.8 
Effect of MDP on kmax, kd, and k’ for NTA  
 To determine the effect of MDP on the kmax, kd, and k’ rate parameters for iron 
release by NTA, rate constants were measured using a constant MDP concentration of 5 
mM in combination with a series of NTA concentrations.  The apparent rate constants for 
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NTA were determined by subtracting the rate for MDP alone from the rate of the mixture.  
A low concentration of MDP was selected for these studies so that the kobs for the mixture 
would be largely due to iron release by NTA.  The data in Figure 5.9 indicated that even 
5 mM MDP would still have a significant allosteric effect on iron release by NTA. 
 The observed/apparent rate constants for iron release by NTA with and without 
the 5 mM MDP are shown in Figure 5.6.  It is obvious that 5 mM MDP and 25 mM PAA 
have essentially the same effect on iron release by NTA.  The data for the MDP/NTA 
mixture is highly linear, so no effort was made to fit them to either equation 5.1 or 5.2.  
Instead, simple linear fit was used, and the slope and intercept, are listed in Table 5.2.  As 
seen in Figure 5.6, 5 mM MDP appears to accelerate iron removal by low concentrations 
of NTA.  But above 40 mM NTA, the net effect of MDP becomes inhibitory.  The rate 
parameters for iron release by NTA in the presence of MDP are listed in Table 5.3. 
 
5.3 
Discussion 
 An early kinetic study on the removal of iron from transferrin by the tricatechol 
ligand 3,4-LICAMS showed that the rate of iron release followed saturation kinetics with 
respect to the ligand concentration (24).  The logical inference from that observation, in 
line with the Michaelis-Menton model for enzyme kinetics, was that the ligand was 
forming a stable mixed-ligand intermediate complex with ferric transferrin, and that the 
rate at saturation represented the dissociation of this intermediate.  Shortly thereafter, 
similar studies using AHA as the chelator also showed saturation kinetics removal (1).  
But this study also included kinetics experiments on the donation of iron to apotransferrin 
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from Fe(AHA)3, and these data showed conclusively that the AHA-Fe-CO3-Tf mixed-
ligand intermediate did not accumulate to detectable levels during iron release.  
Something besides the dissociation of the mixed-ligand intermediate had to be rate-
limiting for iron release, and the authors proposed that it was a slow conformational 
change from the native form of ferric transferrin to a more labile “open” conformation.   
 The Bates mechanism was proposed based purely on kinetic data (1).  However, it 
was subsequently supported by crystal structures, which consistently showed that there 
was a major conformational change between the ferric and apo forms of the protein (25-
27).  This mechanism has been enormously influential on the discussions of iron release 
kinetics.  However, as more studies on iron release have been conducted using a wider 
variety of ligands, it has become clear that there are many ligands that do not show 
simple saturation kinetics for iron removal.  Most of them show “complex” kinetics, 
consisting of a saturation component at low ligand concentrations and a first-order 
component at high ligand concentrations. 
 The Bates mechanism can account for the saturation component.  The bigger 
question has been, what is responsible for the first-order component?  The first order 
component is missing or minimal for AHA (2), catechols (28), and hydroxypyridinones 
(2), which have high pKas and thus carry little net charge at neutral pH.  Conversely, the 
first order term is routinely observed for ligands that contain functional groups such as 
acetate and phosphonate that are more acid and are largely ionized at neutral pH.  
 There are two basic models that attempt to link the ionic nature of the ligand with 
the prominence of a first order component of the iron release.  One model includes two 
separate pathways for iron release.  One pathway consists of the Bates mechanism and 
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accounts for the saturation component of iron release.  The second component is a 
separate pathway that is independent of the conformational change and involves the 
replacement of the synergistic carbonate anion by the incoming anionic ligand 
(2;20;21;29).  According to this model, the k’ term in equation (5.2) is the second order 
rate constant for this second pathway.   
 An alternative explanation for the first order component for iron release is that it 
is essentially an artifact produced by allosteric effects from anions binding to the KISAB 
site on the protein (4).  In this “allosteric” model, the system consists of two forms of 
ferric transferrin that are linked by an anion binding equilibrium.  If one assumes that 
each form of ferric transferrin releases iron via a Bates mechanism, then the effect of 
anion-binding on the observed rate of iron release could be described by equation (5.5). 
 
  
'
max max
'
[ ] [ ] [ ]1
[ ] 1 [ ] [ ] 1 [ ]
A
obs
d A d A
k L k L K Ak
k L K A k L K A
⎛ ⎞ ⎛ ⎞= +⎜ ⎟ ⎜ ⎟+ + + +⎝ ⎠ ⎝ ⎠
 (5.5) 
 
In this equation, KA is the equilibrium constant for anion binding to the KISAB site.  The 
rate parameters are kmax and kd for the “native” form of the protein, and kmax’ and kd’ for 
the “modified” form that is produced by anion binding.  In the special case where the 
anion in equation (5.5) is also the ligand being used to remove the iron, then this model 
attributes the apparent first-order component to a gradual transition from the native 
protein to a modified protein with a larger kmax’  value. 
 At ligand concentrations high enough to saturate the anion binding site, equation 
(5.5) reduces to kobs =  kmax  +  kmax’, i.e. one would still observe saturation kinetics.  
However, one could account for the observed complex kinetics rather easily simply by 
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assuming that the anion binding site is far from saturation and that kmax’ >> kmax.  This is 
illustrated by the family of simulated plots in Figure 5.10. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.  Plots of equation (5.5) simulating the value of kobs for selected rate 
parameters and KISAB anion binding constants.  For all plots, kmax = 0.01 min-1, 
kmax’ = 0.1 min-1, and kd = kd’ = 10 mM.  The KISAB anion binding constants are 
listed next to each plot. 
 
 Figure 5.10 shows plots of equation (5.5) for fixed values of kmax, kmax’, kd and kd’ 
with various values of the anion binding constant KA.  Obviously when KA = 0, one 
obtains simple saturation kinetics with a plateau at the value of kmax.  For a large anion 
binding constant, the data also appear as simple saturation kinetics, with a plateau at kmax 
+ kmax’.  For small values of KA, such that the KISAB site remains far from saturation, 
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the plots indicate complex kinetics, with a saturation component and what appears to be a 
clear first order component.  Thus the allosteric model can account for complex kinetics 
so long as KA is very small and kmax’ >> kmax. 
 In this Chapter we report that MPA and PPA accelerate the rate of iron release by 
both AHA and NTA.  More detailed data on PPA show that this anion does increase the 
value of kmax for both reference ligands.  These observations would be consistent with the 
allosteric model.  However, the unexpected result reported here is that both PAA and 
MDP significantly inhibit iron release by AHA.  Furthermore, the decrease in the rate of 
iron release by AHA can be attributed specifically to a smaller value for kmax.  These new 
results on the effect of PAA and MDP on AHA are not consistent with the allosteric 
model for complex kinetics. 
 The difference between PAA and PPA structurally is one additional methylene 
group between the phosphonate and carboxylate functional groups in PPA.  In Chapter 4, 
our studies on the anion effects of disulfonates, methylenedisulfonic acid (MDS) and 
ethylenedisulfonic acid (EDS) had very similar accelerating effects on iron release by 
AHA.  Thus it is unlikely that the additional group in PPA would lead to a large 
difference in the binding of PAA and PPA as allosteric anions.  Furthermore, the amide 
PAM has virtually the same allosteric effect on iron release as PPA.  Thus the anion-
binding reaction appears to be quite robust to changes in the anion. 
 The most obvious consequence of the elongation of PAA to PPA is the loss of 
iron-binding affinity for the longer anion.  The PPA ligand would form an unstable 7-
membered chelate ring, and thus does not remove any iron from transferrin, whereas 
PAA is a much strong chelator. 
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 The comparison between MDP and EDP is a more complicated.  EDP must also 
form a larger and thus less stable chelate ring.  At lower concentrations, EDP like PPA, 
acts as an allosteric anion but does not remove any iron from the protein.  However, 
higher concentrations of EDP do remove iron, presumably because phosphonate groups 
have a higher affinity for Fe3+ than does the acetate group of PPA.  As soon as the EDP 
concentration is high enough to remove iron from the protein, the effect of this anion on 
iron removal by AHA switches from stimulatory to inhibitory.  In fact, high 
concentrations of EDP have the same inhibitory effect as PAA and MDP on the rate of 
iron release.  Thus there is a clear correlation between inhibition of iron release by AHA 
and the ability of the allosteric anion to bind iron. 
 In the Bates mechanism for the saturation component of iron release by low-
molecular-weight ligands, the protein conformational change occurs prior to any 
interactions with the ligand, and thus the value for kmax should be independent of the 
ligand.  Table 5.3 lists the kmax values for iron removal from both C-terminal and N-
terminal monoferric transferrins by a series of ligands.  There is clearly a variation in kmax 
among ligands, particularly for the N-terminal site.  The new data on how ligands such as 
PAA can also bind to the KISAB site provides a possible reason for this variation in kmax.  
If this hypothesis is correct, then NTA and DTPA represent the extreme in self-inhibition 
by chelating agents, since they have kmax values of zero. 
 McGillivray et al. (27) have reported crystal structures for the ferric complex of 
the recombinant N-lobe that shows disorder of the synergistic carbonate anion.  They 
have proposed that this results from a mixture of two conformations.  In one 
conformation, the carbonate is bound as expected as a bidentate ligand.  In the second 
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conformation, the carbonate has rotated and is coordinated as a monodentate ligand.  This 
obviously frees one coordination site for an incoming ligand. 
 The inhibition of iron release by AHA is associated specifically with chelating 
anions, but not monodentate anions.  The implication is that the inhibiting anions are 
binding as bidentate ligands to the iron.  This change in the conformation of the carbonate 
could provide one coordination site.  The second coordination site could be generated by 
going from 6-coordinate to 7-coordinate iron, or by the displacement of one of the protein 
ligands.  It has been proposed that when iron binds to apoTf, coordinate bonds to the two 
tyrosine residues form first, and the bonds to histidine and aspartic acid form later as the 
protein structure moves toward a closed conformation (30).  Thus one would expect that 
either the histidine or the aspartic acid would be more likely to dissociate early in the iron 
release process.  The aspartic acid is the only protein ligating group from domain I in 
each lobe.  He and Mason (31) have suggested that the weakening of the coordinate bond 
to the aspartate, in conjunction with the binding of a chelating agent or KISAB anion, is 
an early step in iron release.  
 Harris et al. (29) used citrate to study the rate of metal release from the C-terminal 
site for Fe3+, Ga3+, In3+, Al3+, and Tb3+.  They showed that the value of kmax was very 
strongly dependent on the identity of the metal ion, with values ranging from 0.004 min-1 
for Fe3+ to ~0.7 min-1 for In3+ and Al3+ to ~ 2.0 min-1 for Ga3+  and Tb3+.  This is another 
indication that the magnitude of kmax is sensitive to the making and/or breaking of metal 
ligand bonds. 
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Table 5.4 
kmax and k’ parameters for iron release from C-terminal monoferric transferrin 
 
Ligand 
103 kmax (min-1)   
C-terminal monoferric Tf  
103 kmax (min-1)  
N-terminal monoferric Tf 
 
Reference 
PPi 7.7 51 (3) 
DHBA 9.18 50.4 (32) 
AHA 13.6a 46.6 (2) 
L1 7.4  44.7 (2) 
3,4-LICAMS 13.5 39 (28) 
1H2P 12.9 36.2 (2) 
Citrate 4.0 37.1 (33) 
MDP 10.0a 30.8 (20) 
PAA 17a 27.9 (20) 
Methyl-PAA 26a 26.1 (20) 
L-Mimosine 23 25.9 (32) 
EDTA 6.4 24.9 (8) 
EDTP 8.3 20.4 (8) 
Ethyl-PAA 40a 20.0 (20) 
NTP 9.8 15.8 (6) 
DTTP 7.9 4.7 (11) 
NTA 0a 0 (6) 
DTPA 0 0 (11) 
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The two-pathway model 
 Based on the new results reported here, it does not appear that the first-order 
component for iron release is associated with an allosteric effect from the chelating agent.  
The alternative explanation is that there is a separate first-order pathway for iron release.  
There is considerable evidence that the first-order component is directly associated with 
the displacement of the synergistic carbonate anion.  Schlabach and Bates established 
structural criteria for anions which are capable of replacing the synergistic carbonate 
(22).  These were later refined based on epr studies by Dubach et al (34) on a more 
extensive set of anions.  In general, synergistic anions form 5- or 6-membered chelate 
rings.  One coordination site is occupied by a carboxylate group.  The second 
coordinating group may be another carboxylate group, but can also be an alcohol, a 
ketone, or an amine.  If there is a methylene group within the chelate ring, there is a steric 
restriction that the methylene can have one substituent, but not two.  For example, lactate 
can serve as a synergistic anion, but 2-methyllactate cannot (22).  The ligands which 
typically follow simple saturation kinetics (hydroxamates, catechols, and 
hydroxypyridones) have structures that do not conform to this standard structural model 
for a synergistic anion.  Thus the hypothesis was that the first order pathway requires the 
incoming ligand to replace the synergistic carbonate (6;11;35). 
 Brook et al. (21) have provided additional data to support this hypothesis.  The 
kinetics of iron release were evaluated for PAA, benzyl-PAA, and dibenzyl-PAA.  The 
monosubstituted benzyl-PAA showed complex kinetics with only slight changes in the 
rate parameters from those for PAA.  However, disubstitution in dibenzyl-PAA reduced 
k’ by an order of magnitude (21).   
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 The ligand that removes iron most quickly via a first-order process is 
pyrophosphate (7).  Bailey et al. (36) reacted a lysine near the metal-binding site of 
ovotransferrin with hydroxypyruvate and created an endogenous, covalently bound 
synergistic anion.  This modified protein binds iron in the absence of carbonate.  Bailey 
et al. (36) conducted kinetic studies using pyrophosphate to release the iron both from the 
native Fe-CO3-ovoTf complex and the carbonate-free Fe-OvoTf’ complex of the 
chemically modified protein.  Pyrophosphate removed iron from the native complex via 
complex kinetics, with a value of k’ very similar to that reported for serum transferrin.  
However, iron release from the modified protein changed to simple saturation kinetics, 
with k’ = 0, providing strong evidence that replacement of the carbonate is a key 
requirement for the first-order process. 
 Kinetic studies have also been conducted on iron release from the R124A mutant 
of the transferrin N-lobe (37).  Arginine 124 is a key residue that hydrogen bonds to the 
synergistic carbonate to strengthen the Fe-CO3-Tf ternary complex.  The R124A mutant 
still binds iron using carbonate as the synergistic anion, but the complex is much weaker.  
Rates of iron release from the R124A mutant were studied using both AHA and 
deferiprone.  In both cases, iron release followed a simple first order process, with k’ 
parameters of 57 M-1min-1 for AHA and 980 M-1min-1 for deferiprone.  The largest k’ 
value reported for wild type N-lobe transferrin is 0.4 M-1min-1 for iron removal by 
pyrophosphate.  Thus the disruption in R124A of the hydrogen-bonding network that 
holds the carbonate in place changes the kinetics from essentially pure saturation kinetics 
to simple first-order kinetics with a rate constant 3 to 4 orders of magnitude larger than 
any k’ value reported for the wild-type protein. 
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 These previous studies are all consistent with a reaction pathway that involves the 
replacement of the synergistic carbonate anion.  The present work on allosteric anion 
binding shows that anions have quite distinct effects on the saturation and first-order 
components for iron release and provides evidence that the binding of the ligand as an 
allosteric anion is very unlikely to generate an apparent first-order process for iron 
release. 
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Chapter 6 
A Comparative Study of Iron Removal from C-terminal Monoferric Human Serum 
Transferrin by NTA and its Phosphonate Analogue PIDA 
 
6.1 
Introduction 
 This chapter describes the kinetics of iron release from C-terminal monoferric 
transferrin by N-(phosphonomethyl)iminodiacetic acid (PIDA).  The results are compared 
with data on iron release by nitrilotriacetic acid (NTA) alone and by a mixture of NTA 
and methylphosphonic acid (MPA).  These data are used to compare the role of the 
phosphonate group when incorporated into the ligand PIDA versus the role of the free 
phosphonate group in a mixture with NTA. 
 The tripodal phosphonate analogues of NTA such as PIDA, N,N-
bis(phosphonomethyl)glycine (DPG) and nitrilotris(methylenephosphonic acid) (NTP) 
have been studied by our group (1).  The rates of iron removal from diferric human serum 
transferrin by these phosphonate analogues of NTA were studied, and the data were fit to 
equations 6.1 and 6.2, the empirical equations used to describe simple saturation kinetics, 
 
                             
max [ ]
[ ]obs d
k L
k
k L
= +                                                  (6.1) 
and complex kinetics, 
                          
max[ ] '[ ]
[ ]obs d
k Lk k L
k L
= ++                                       (6.2)
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 The ligands PIDA, DPG and NTP followed complex kinetics for iron release from 
diferric transferrin, whereas the tricarboxylate analogue NTA showed simple first order 
kinetics with respect to the NTA concentration (1).  It has been proposed that equation 
6.2 reduces to a simple first order dependence for NTA due to a very small kmax.  
Previous studies have also indicated that the phosphonate group has a higher affinity for 
Fe(III) than the carboxylate moiety in these ligands (1;2).  This chapter compares the 
effect of the one phosphonate group along with two carboxyl moieties in PIDA with that 
of the three carboxyl moieties in NTA on iron release from transferrin. 
 
6.2 
Results 
6.2.1 
Iron release from C-terminal monoferric transferrin by PIDA 
 Iron release from C-terminal monoferric transferrin was followed over the 
concentration range of 1 to 125 mM PIDA.  The data for PIDA is shown in Figure 6.1. 
There is an increase in kobs between 0 and 15 mM concentrations, after which the plot 
starts to curve but does not reach a plateau.  On the contrary, the values for kobs continue 
to increase linearly with increasing ligand concentration.  In other words, the rate follows 
a combination of saturation and first-order kinetics that can be described by equation 6.2. 
The data in Figure 6.1 have been fit to both equations 6.1 and 6.2, and the rate parameters 
are listed in Table 6.1.  The data for iron release from C-terminal monoferric transferrin 
fits well with the 3 parameter fit to equation 6.2. 
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Figure 6.1.  Rate constants for iron release from C-terminal monoferric transferrin 
by PIDA in 0.1 M hepes buffer at pH 7.4 and 25 °C. 
 
Table 6.1.  
Rate parameters for iron removal from C-terminal monoferric transferrin by PIDAa 
    a 25 oC, 0.1 M Hepes, pH 7.4 
    bData fit using two adjustable parameters to eq (6.1) 
   cData fit using three adjustable parameters to eq (6.2)  
 kmax (min-1) x 103 kd  x 103 (M) k' (M-1 min-1) 
PIDAc 10.1 ± 0.5 5.5 ± 0.8 0.060 ± 0.005 
PIDAb 17.12 ± 0.93 16.30 ± 2.9 - 
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 In earlier studies (1), the PIDA ligand sample contained 10% of an impurity 
identified as (hydroxymethyl)phosphonic acid (HMP), so it was possible that the first 
order parameter for iron release was due to anion effects of HMP.  The PIDA ligand used 
in this study was commercially available and did not contain any HMP impurity, so the 
appearance of the first order parameter is solely due to PIDA and is not a mere anion 
effect. 
 
6.2.2 
Effect of phosphonate on iron release by NTA 
 The effect of phosphonate anions on the rate of iron release by 100 mM NTA has 
been studied as described in Chapter 5.  We measured the rates of iron release from C-
terminal monoferric transferrin by 100 mM NTA and by a mixture of 100 mM NTA and 
increasing concentrations of MPA.  The results are shown in Figure 6.2.  The mixtures of 
NTA and MPA had higher rates than NTA by itself.  MPA behaves as a simple allosteric 
anion and accelerates the rate of iron release by 100 mM NTA by binding at the KISAB 
site on the protein. 
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Figure 6.2.  Plots of kobs for the removal of iron from C-terminal monoferric 
transferrin by 100 mM nitrilotriacetic acid (NTA) in the presence of 
methanephosphonate (MPA,●) at 25 ºC in 0.1 M Hepes, pH 7.4. 
 
6.2.3 
Effect of different modes of phosphonate group on iron release pathways 
 One of the goals of this study was to evaluate the effect of the phosphonate group 
when incorporated into the ligands versus the effect of a free phosphonate group in a 
mixture with the ligand.  To observe the effect of a phosphonate incorporated as a moiety 
into the ligand, we have evaluated iron release by PIDA, which contains two carboxylate 
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groups and a phosphonic acid group.  When compared with the structure of NTA, it can 
be seen as one carboxyl group of NTA that has been replaced with a phosphonic acid 
group.  To compare the effect of the free phosphonate group, we performed experiments 
with mixtures of equimolar concentrations of NTA and MPA.  The pseudo first-order rate 
constants for iron removal by NTA from C-terminal monoferric transferrin were 
determined as reported previously (1;2).  Iron removal by NTA shows a first order 
dependence on the concentration of NTA, with a zero intercept, as can be seen in Figure 
6.3, indicating the absence of any other pathway at low concentrations of NTA.  Figure 
6.3 also shows the rate constants for iron removal by equimolar mixtures of NTA and 
MPA.  For both NTA alone and the NTA/MPA mixtures, we limited the studies to NTA 
concentrations > 25 mM.  At lower concentrations of NTA, very little iron was removed 
and the rate constants were difficult to determine. 
 As shown in Figure 6.3, iron release from C-terminal monoferric transferrin by 
the mixture of NTA and MPA shows a linear dependence of the rate constant kobs on the 
ligand concentration over the concentration range of 25-100 mM of the mixture.  The 
linearity of the plot and the nonzero intercept are consistent with the equation for 
complex kinetics assuming that [L] >> kd over the available range of ligand 
concentration.  Under these conditions, equation (6.2) for complex kinetics, reduces to 
equation (6.3), a simple linear equation with a slope of k' and a y-intercept of kmax. 
 
                                         ]['max Lkkkobs +=                                                (6.3) 
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Under these conditions kd, which is the concentration of ligand required to reach half 
saturation, could not be determined.  This type of observation has been made by iron 
release from C- and N-terminal transferrin by PAA (3;4).  In these previous studies it was 
assumed that the plots of kobs versus PAA concentration would curve towards zero at 
lower ligand concentrations.  This curvature has now been demonstrated by the results in 
Chapter 3 for iron release from C-terminal monoferric transferrin by low ligand 
concentrations of PAA and its alkyl derivatives. 
 
Figure 6.3.  Rate constants for iron removal from C-terminal monoferric transferrin 
by PIDA, by NTA and by equimolar mixtures of NTA and MPA at 25 ºC in 0.1 M 
Hepes, pH 7.4. 
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 The NTA/MPA mixtures have higher rate constants than NTA alone, which 
demonstrates yet again the accelerating effect of the simple anion MPA on the rate of 
iron release by NTA.  Also, the presence of MPA introduces a non-zero kmax value for 
iron release by NTA in the mixture.  It appears that MPA in the mixture with NTA acts as 
a simple allosteric anion, and by binding to the KISAB site, it accelerates the rate of iron 
release by increasing the saturation rate parameter kmax, which is otherwise not seen for 
NTA.  The allosteric binding of MPA also produces a small increase in the k' parameter 
for the first-order pathway. 
 The studies on iron release by PIDA included data at lower ligand concentrations, 
such that the initial curvature in the plot in Figure 6.3 is clearly visible.  The appearance 
of the curvature at low ligand concentrations clearly displays the presence of a saturation 
pathway.  The rate parameters derived from the data in Figure 6.3 are listed in Table 6.2.  
The value of kmax obtained from the three-parameter fit of the PIDA data to eq (6.2) is 
essentially the same as the kmax for NTA in the presence of equimolar MPA.  However, 
incorporating the phosphonate group into the ligand structure results in a dramatic 
decrease in the k' parameter for PIDA, even though the NTA/MPA mixture showed a 
slight increase in k'. 
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Table 6.2. 
Rate parameters for iron release from C-terminal monoferric transferrin 
 kmax (min-1) x 103 kd  x 103 (M) k'  (min-1M-1) 
NTA - - 0.325 ± 0.012 
NTA+MPA 9.4 ± 1.1 - 0.390 ± 0.016 
PIDA 10.1 ± 0.5 5.5 ± 0.8 0.060 ± 0.005 
NTPa 9.8 ± 2.0 7.6 ± 1.1 0.053 ± 0.006 
a Results from ref (2) 
 
6.3 
Discussion 
 In Chapters 4 and 5, we studied extensively the effect of sulfonates, 
diphosphonates and phosphonocarboxylates on the kinetic pathways of iron removal from 
transferrin.  In all these studies, the effect of anions was studied using mixtures of the 
anion and a reference ligand.  This chapter focused on the effect of the phosphonate 
group in two different modes on iron release. 
 In the NTA/MPA mixtures, the phosphonate group can only act as an allosteric 
anion.  Anions have been reported previously to alter the rates of iron release, and this 
effect has been attributed to their selective binding to an allosteric binding site usually 
referred to as KISAB site (5).  MPA increases the rate of iron release by NTA in the 
mixture, presumably by binding to the proposed allosteric site of the protein.  This anion 
binding introduces a significant value for kmax for iron release by NTA, and thus appears 
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to accelerate the conformational change in the protein.  The results for the MPA in the 
mixture are consistent with the allosteric anion effects reported in Chapters 4 and 5 for 
other non-coordinating anions. 
 The free MPA group does not seem to have much effect on the k' value for NTA.  
There is a modest increase in k' for the MPA/NTA mixtures.  This minor change in k' is 
nonetheless in contrast with the effect of the non-chelating bifunctional anions MDS and 
PPA, both of which cause a reduction in k' for iron release by NTA, as described in 
chapters 4 and 5, respectively. 
 Incorporation of the phosphonate group into the ligand PIDA improves its iron 
binding affinity and makes it easier to study iron release at lower ligand concentrations.  
Thus the curvature at low ligand concentrations, consistent with a saturation component 
for iron release, can be easily observed for PIDA.  The kmax value for PIDA of 0.010 min-
1 is essentially the same as that of the triphosphonate ligand NTP (2), as shown in Table 
6.2.  The surprising result is that the mixture of NTA/MPA has the same kmax value.  This 
indicates that the increase in kmax observed upon going from NTA to PIDA and NTP can 
be attributed to the binding of the phosphonate groups of these ligands to the KISAB site. 
 The incorporation of the phosphonate group into PIDA also results in a distinct 
decrease in the first order component, k' from 0.325 M-1 min-1 for NTA to only 0.060 M-1 
min-1 in PIDA.  This decrease in k' is quite different from the NTA/MPA mixtures, which 
show a slight increase in k'.  Thus it is difficult to attribute the decrease in k' to allosteric 
binding of a phosphonate group of PIDA. 
 A k' value of ~0.05 M-1 min-1 seems to be characteristic of aminophosphonic 
acids.  The k' value for EDTA of 0.114 M-1 min-1 decreases to 0.036 for 
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ethylenediaminetetra(methylenephosphonic acid), EDTP (6), and the k' value for 
diethylenetriaminepenta(methylenephosphonic acid), DTPP is 0.070 M-1 min-1 (7).  The 
results reported here for PIDA suggest that only a single phosphonic acid group is 
necessary for this reduction in k'. 
 In chapter 5 we discussed the observation that chelating anions had very different 
effects than non-chelating anions on iron release by the reference ligands.  Thus one 
possibility is that the decrease in k' is related to the ability of the 
aminomethylphosphonate functional group to form a stable chelate ring.  However, other 
phosphonate chelating agents, such as PAA and MDP, retain high k' values of 0.38 and 
0.18 M-1 min-1, respectively, and pyrophosphate has a very large k' value of 0.84 M-1 min-
1 (2).  Thus it is difficult to attribute the drop in k' directly to some sort of chelate effect. 
 The non-chelating, bifunctional anions PPA and MDS also caused a reduction in 
the k' value for iron removal by NTA.  Thus one could speculate that the decrease in k' 
does reflect the binding of PIDA to the KISAB site, but as a bifunctional anion, similar to 
PPA and MDS, as opposed to the monofunctional MPA.  Since the amide PAM has 
essentially the same allosteric effect as PPA, it is possible that the PIDA could bind to the 
allosteric site using a combination of the phosphonate and amine group of PIDA.  
Alternatively, the PIDA could bind using a combination of the phosphonate group and 
one of the carboxylate groups. 
 The absence of a saturation component for iron release by NTA has been linked to 
the weaker binding of the carboxylate group to the protein as an anion as compared to the 
phosphonate group (2).  The appearance of a consistent kmax value for iron removal by the 
NTA/MPA mixture, PIDA, and NTP appears to be due to the binding of the phosphonate 
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group to the KISAB site on the protein.  This binding of the phosphonate anion to ferric 
transferrin as an anion to the cationic side chains of the protein appears to be different 
from the allosteric KISAB site.  Thus we speculate the presence of more than one anion 
binding site in the transferrin and further studies are needed to confirm these 
speculations. 
 The first order pathway has been proposed to be associated with the replacement 
of synergistic anion by the incoming ligand, followed by the fast dissociation of the iron 
ligand complex (1).  The incorporation of the phosphonate group into the ligand in PIDA 
and NTP reduces the k' parameter for the first order pathway.  In contrast, the binding of 
the free phosphonate group of MPA increases kmax.  Thus the reduction in k' for PIDA 
and NTP cannot be attributed to the binding of a phosphonate arm of the ligand to the 
KISAB site.  This suggests that the reduction in k' may be related to a direct binding of 
the incoming ligand to the ferric ion in the iron-protein complex during the iron removal 
reaction.  However, the structure of this possible ligand-iron-carbonate-protein 
quaternary complex is not known. 
 The bifunctional, non-chelating anion MDS and PPA also reduce the value of k' 
for the first order pathway.  It is possible that the different allosteric effects of the 
monofunctional anion MPA and these bifunctional anions reflect the existence of more 
than one KISAB site.  The possibility of multiple KISAB sites has been suggested by 
Halbrooks et al based on kinetic studies of mutant transferrins produced by site-directed 
mutagenesis (8).  The ability of the aminophosphonate ligands to increase kmax while 
decreasing k' could reflect their ability to bind to two different KISAB sites. 
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Chapter 7  
Conclusions 
 
 The ligand-dependence of the rate of iron release from transferrin by various low 
molecular weight ligands has shown three different patterns, described as saturation 
kinetics, first-order kinetics, and complex kinetics.  In most cases, saturation kinetics are 
attributed to the Bates mechanism (1) for iron release, in which the rate-limiting step for 
iron removal is a conformational change in the protein.   
 It is well known that various non synergistic anions affect the rate of iron release 
(2;3). It has been proposed that these anion effects reflect the binding of the anions to an 
allosteric binding site known as the kinetically significant allosteric anion binding 
(KISAB) site (4-6).  Despite several attempts to locate this site, the exact location of the 
KISAB site is still unknown (7;8). 
 There has not been a consensus on the mechanism for the first-order component 
for iron release.  Our group has proposed that the first-order component represents a 
reaction pathway that is independent of the protein conformation change, one in which 
the rate limiting step is the replacement of the synergistic carbonate anion by the 
incoming ligand, which destabilizes the Fe-L-Tf complex and triggers iron release (9-12).  
Others have proposed that the first-order component arises because anionic ligands can 
bind to the KISAB site, and that this allosteric effect increases the kmax  values for the 
protein conformational change as the ligand concentration increases (4;6;13).  
 This dissertation focuses on the effect of three main classes of anions: sulfonates, 
phosphonates and phosphonocarboxylates.  These anions can be further divided into two 
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types: (a) simple, non-chelating anions and (b) anions which are also competent chelating 
agents that can remove iron from transferrin.  In our studies, the impact of these anions 
on the iron release from C-terminal monoferric transferrin has been evaluated using two 
types of reference ligands.  Acetohydroxamic acid (AHA) and deferiprone (L1) remove 
iron exclusively via a saturation pathway (1;14), while NTA and DTPA remove iron 
exclusively by a first order pathway (9;10).  The objective was to evaluate the effect of 
the anions on the individual iron release pathways. 
The non-chelating anions consistently increase the rates of iron release by all 
ligands.  The anions appear to act primarily by increasing the kmax value associated with 
the saturation pathway (eq 1.1 in chapter 1).  This increase was apparent even for NTA, 
which in the absence of the anions has a kmax value of zero.  This increase in kmax 
presumably reflects the binding of the anions to the KISAB site on transferrin.   
The anion effects are consistently higher for bifunctional anions (e.g. 
phosphonoacetic acid) compared to the individual anionic functional groups (e.g. acetate 
and methylphosphonate).  However, there were not large variations in the anion effects 
among the bifunctional non-chelating anions. 
 The effect of non-chelating anions on the first-order pathway are somewhat 
variable.  The rate of iron release via this pathway is represented by the k' parameter in eq 
(1.2) in chapter 1.  Non-chelating anions reduce the k' for NTA by a modest amount.  
Conversely, they increase the k' value iron release by AHA.  In general, these changes in 
k' have less effect on the overall rate of iron release than the consistent increases in kmax. 
 At the beginning of this study, we anticipated that the analysis of the kinetic data 
would be more complicated for experiments that involve chelating anions because it 
Sharma, Rashmi Subhash Chander, 2010, UMSL, p.166 
 
166 
 
would be necessary to account for the simultaneous release of iron by the reference 
ligand and the chelating anion.  We developed methods to partition the overall rate 
constant for iron release into individual components attributed to the reference ligand and 
the chelating anion.  We expected that once the overall rate was properly partitioned 
between the two components, that the allosteric effect due to the binding of the chelating 
anions would closely resemble the effect of the non-chelating anions.  Unexpectedly, the 
chelating anions PAA and MDP significantly reduced the kmax value for the reference 
ligand.  This reduction in kmax appears to be specifically associated with the ability of the 
anion to form a stable chelate ring with the Fe3+.  This obviously requires some 
conformational change in the protein to expose vacant coordination sites.  We speculate 
that this could involve a change in the coordination mode of the synergistic carbonate 
from bidentate to monodentate, possibly combined with the dissociation of the 
carboxylate group from the aspartic acid. 
 Although the mode of binding of the chelating anions is still uncertain, the 
observed reduction in kmax values associated with the chelating anions does help 
differentiate between alternative mechanisms for iron release.  The Bertini mechanism (4) 
proposes that the first-order term is an artifact that appears because the anionic chelating 
agent is binding to the KISAB site to gradually increase the kmax value.  We have now 
shown that the binding of these chelating anions to the protein decreases, rather than 
increases, the rate of iron release.  This is strong evidence against the Bertini mechanism. 
 The anion effects for both non-chelating and chelating anions were studied using 
mixtures of the anions and the reference ligands.  We also evaluated the effect of the 
phosphonate anion when it is incorporated into the chelating agent PIDA versus the effect 
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of MPA in an equimolar mixture with NTA.  In both PIDA and the MPA/NTA mixture, 
the phosphonate binds to the KISAB site and causes the expected increase in kmax for iron 
release via a saturation pathway.   
 The free MPA anion causes a small increase in the k' parameter for iron release by 
NTA.  However, incorporating the phosphonate group into PIDA drastically reduces the 
k' value for iron release via the first-order process.  A similar reduction in k' has been 
reported for the ligand NTP (9;15), in which all three of the carboxylate groups of NTA 
are replaced by phosphonic acid group.   
 We have proposed that the first-order pathway is associated with ligands that can 
replace the synergistic carbonate anion.  Work by Schlabach and Bates (16) and by 
Dubach et al. (17) have established structural criteria for ligands that can serve as a 
synergistic anion.  According to the Bates-Dubach model, NTA, PIDA and NTP should 
all be able to replace the carbonate.  Thus there is no obvious reason why k' is so much 
smaller for NTP and PIDA compared to NTA.  Similar unexpected decreases in k’ have 
been observed for other phosphonates that meet the Bates-Dubach model for a viable 
synergistic anion (18).  Thus it appears that (a) the Bates-Dubach model is incomplete, 
and some structural feature of the phosphonates is unexpectedly destroying their ability to 
replace the synergistic bicarbonate, or (b) our original hypothesis that k’ is intimately 
linked to the replacement of the carbonate is incorrect.  Further work is needed to resolve 
this issue. 
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